Skin care compositions

ABSTRACT

Dermatological and cosmetic compositions and methods are provided to reduce the appearance of biological and/or environmentally-caused aging.

CROSS-REFERENCE

This application is a continuation application which claims the benefitof U.S. application Ser. No. 12/167,094, filed Jul. 2, 2008; whichclaims the benefit of U.S. Provisional Application No. 60/947,607, filedJul. 2, 2007, both of which applications are incorporated herein byreference in their entirety.

BACKGROUND OF THE INVENTION

Maintaining a youthful appearance is of great importance to many people.There is a need for treatments designed to extend or promote theyouthful appearance of skin.

SUMMARY OF THE INVENTION

One aspect of the present invention is dermatological and cosmeticcompositions that help to reduce the appearance of biological and/orenvironmentally-caused aging comprising: a reverse transcriptasecomponent of telomerase; one or more growth factors; at least twoacylated peptides; and optionally, at least one skin benefit agentselected from the group consisting of antioxidants, humectants andmoisturizing agents.

A second aspect of the invention is cosmetic or dermatologicalcompositions comprising: an inhibitor of a component of telomerase; oneor more growth factors; at least two acylated peptides; and optionally,at least one skin benefit agent selected from the group consisting ofantioxidants, humectants and moisturizing agents.

A third aspect of the invention is cosmetic or dermatologicalcompositions comprising: a reverse transcriptase component of atelomerase; an Epidermal Growth Factor; a Keratinocyte Growth Factor; aTransforming Growth Factor-β1; at least one myristoylated peptide; atleast one antioxidant; at least one humectant or moisturizing agent; anda cosmetically suitable vehicle.

A fourth aspect of the invention is cosmetic or dermatologicalcompositions comprising: a reverse transcriptase component of atelomerase; a Vascular Endothelial Growth Factor; a Keratinocyte GrowthFactor; a Transforming Growth Factor-β1; at least one myristoylatedpeptide; at least one antioxidant; at least one humectant ormoisturizing agent; and a cosmetically suitable vehicle.

A fifth aspect of the invention is cosmetic or dermatologicalcompositions comprising: an inhibitor of a component of a telomerase; anEpidermal Growth Factor; a Keratinocyte Growth Factor; a TransformingGrowth Factor-β1; at least one myristoylated peptide; at least oneantioxidant; at least one humectant or moisturizing agent; and acosmetically suitable vehicle.

A sixth aspect of the invention is cosmetic or dermatologicalcompositions comprising: an inhibitor of a component of a telomerase; aVascular Endothelial Growth Factor; a Keratinocyte Growth Factor; aTransforming Growth Factor-β1; at least one myristoylated peptide; atleast one antioxidant; at least one humectant or moisturizing agent; anda cosmetically suitable vehicle.

Another aspect of the invention provides methods for improving theappearance of skin comprising applying topically to the skin acomposition comprising: a reverse transcriptase component of atelomerase; one or more growth factors; at least two acylated peptides;and optionally, at least one skin benefit agent selected from the groupconsisting of antioxidants, and humectants and moisturizing agents.

A further aspect of the invention provides methods for improving theappearance of skin comprising applying topically to the skin acomposition comprising: an inhibitor to a component of a telomerase; oneor more growth factors; at least two acylated peptides; and optionally,at least one skin benefit agent selected from the group consisting ofantioxidants, humectants and moisturizing agents.

In some embodiments of the invention, the composition further comprisesan RNA component of telomerase.

In some embodiments of the invention, the reverse transcriptasecomponent of telomerase has an amino acid sequence with at least 90%,95%, 98%, or 99% sequence homology to the amino acid sequence of atelomerase reverse transcriptase of an animal. In other embodiments ofthe invention, the RNA component of telomerase has an amino acidsequence with at least 90%, 95%, 98%, or 99% sequence homology to theamino acid sequence of a telomerase RNA of an animal. In yet otherembodiments of the present invention the RNA component of telomerase hasan amino acid sequence with at least 90%, 95%, 98%, or 99% sequencehomology to the amino acid sequence of human telomerase RNA (hTR). Inother embodiments of the present invention, the reverse transcriptasecomponent of telomerase has an amino acid sequence with at least 90%,95%, 98%, or 99% sequence homology to the amino acid sequence of a humantelomerase reverse transcriptase (hTRT). In other embodiments of thepresent invention, the RNA component of telomerase comprises humantelomerase RNA (hTR). In other embodiments of the present invention, thereverse transcriptase component of telomerase comprises human telomerasereverse transcriptase (hTRT). In some embodiments of the invention thecompositions comprise a telomerase reverse transcriptase and atelomerase RNA. In some of the embodiments of the invention, thetelomerase reverse transcriptase is recombinant telomerase reversetranscriptase. In some of the embodiments of the invention, thetelomerase RNA is recombinant telomerase RNA.

In some embodiments of the invention, the inhibitor of a component oftelomerase is an antibody. In some embodiments of the invention, theantibody to a component of telomerase has an amino acid sequence with atleast 90%, 95%, 98%, or 99% sequence homology to the amino acid sequenceof an antibody to a component of animal telomerase. In other embodimentsof the invention, the antibody to a component of telomerase has an aminoacid sequence with at least 90%, 95%, 98%, or 99% sequence homology tothe amino acid sequence of an antibody to a component of humantelomerase. In some embodiments of the invention, the antibody comprisesa human telomerase RNA (hTR) antibody. In other embodiments of theinvention, the antibody to telomerase comprises a human telomerasereverse transcriptase (hTRT) antibody.

In some embodiments of the invention, the one or more growth factorscomprise an Epidermal Growth Factor. In other embodiments of theinvention, the Epidermal Growth Factor is a human Epidermal GrowthFactor. In some embodiments of the invention, the one or more growthfactors comprise a Vascular Endothelial Growth Factor. In someembodiments of the invention, the one or more growth factors comprisehuman endothelial growth factor. In some embodiments of the invention,the one or more growth factors comprise one or more Fibroblast GrowthFactors. In some embodiments of the invention, the one or more growthfactors comprise a Keratinocyte Growth Factor. In some embodiments ofthe invention, the one or more growth factors comprise a humanKeratinocyte Growth Factor. In some embodiments of the invention, theone or more growth factors comprise KGF-1. In other embodiments of theinvention, the one or more growth factors comprise KGF-2. In someembodiments of the invention, the one or more growth factors compriseTransforming Growth Factor-β1. In some embodiments of the invention, theone or more growth factors comprise a human Transforming GrowthFactor-β1. In some embodiments of the invention, the one or more growthfactors comprise Vascular Endothelial Growth Factor. In some embodimentsof the invention, the one or more growth factors comprise a humanVascular Endothelial Growth Factor. In some embodiments of theinvention, the one or more growth factors is one or more recombinantgrowth factors.

In some embodiments of the invention, the at least two acylated peptidescomprise a first acylated peptide which is myristoylated. In someembodiments of the invention, the at least two acylated peptidescomprise a second acylated peptide which is myristoylated. In someembodiments of the invention, the at least two acylated peptidescomprise a first acylated peptide which is myristoylated and a secondacylated peptide which is palmitoylated. In some embodiments of theinvention, the at least two acylated peptides comprise a third acylatedpeptide and optionally four or more acylated peptides.

In some embodiments of the invention, the compositions comprise at leastone antioxidant, independently chosen from the group consisting ofascorbic acid and its salts, ascorbyl esters of fatty acids, ascorbicacid derivatives (e.g., magnesium ascorbyl phosphate, sodium ascorbylphosphate, ascorbyl sorbate), tocopherol, tocopherol sorbate, tocopherolacetate, other esters of tocopherol, butylated hydroxy benzoic acids andtheir salts, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid(commercially available under the tradename Trolox®), gallic acid andits alkyl esters (e.g., propyl gallate), nordihydroguaiaretic acid,bioflavonoids, quinones, and ubiquinones including Coenzyme Q and itsderivatives. In some embodiments of the invention, the compositioncomprises a green tea extract. In some embodiments of the invention, theat least one antioxidant is ubiquinone. In some embodiments of theinvention, the at least one antioxidant is green tea extract. In someembodiments of the invention, the at least one antioxidant is tocopherolacetate.

In some embodiments of the invention, the composition, one or morehumectants are selected from the group consisting of D,L-panthenol,D-panthenol, sodium hyaluronate, methylsilanol mannuronate and butyleneglycol.

In some embodiments, Telomerase RNA is present in compositions of thepresent invention at concentrations of at least from about 0.000001% w/wto about 0.01% w/w. In some embodiments, Telomerase RNA is present incompositions of the present invention at concentrations of at least fromabout 0.000005% w/w to about 0.005% w/w. In some embodiments, TelomeraseRNA is present in compositions of the present invention atconcentrations of at least from about 0.00001% w/w to about 0.001% w/w.In some embodiments, Telomerase RNA is present in compositions of thepresent invention at concentrations of at least from about 0.00005% w/wto about 0.001% w/w. In some embodiments, Telomerase RNA is present incompositions of the present invention at concentrations of at least fromabout 0.0001% w/w to about 0.001% w/w. In some embodiments, TelomeraseRNA is present in compositions of the present invention atconcentrations of more than about 0.000006% w/w. In some embodiments,Telomerase RNA is present in compositions of the present invention atconcentrations of more than about 0.00006% w/w. In some embodiments,Telomerase RNA is present in compositions of the present invention atconcentrations of more than about 0.0006% w/w. In some embodiments,Telomerase RNA is present in compositions of the present invention atconcentrations of more than about 0.005% w/w. In some embodiments,Telomerase RNA is present in compositions of the present invention atconcentrations of more than about 0.006% w/w. In some embodiments,Telomerase RNA is present in compositions of the present invention atconcentrations of more than about 0.01% w/w. In some embodiments,Telomerase RNA is present in compositions of the present invention atconcentrations of less than about 0.01% w/w. In some embodiments,Telomerase RNA is present in compositions of the present invention atconcentrations of less than about 0.001% w/w. In some embodiments,Telomerase RNA is present in compositions of the present invention atconcentrations of less than about 0.0007% w/w. In some embodiments,Telomerase RNA is present in compositions of the present invention atconcentrations of less than about 0.0006% w/w. In some embodiments,Telomerase RNA is present in compositions of the present invention atconcentrations of less than about 0.0001% w/w.

In some embodiments, Telomerase reverse transcriptase (RT) is present incompositions of the present invention at concentrations of at least fromabout 0.000001% w/w to about 0.01% w/w. In some embodiments, Telomerasereverse transcriptase (RT) is present in compositions of the presentinvention at concentrations of at least from about 0.000005% w/w toabout 0.005% w/w. In some embodiments, Telomerase reverse transcriptase(RT) is present in compositions of the present invention atconcentrations of at least from about 0.00001% w/w to about 0.001% w/w.In some embodiments, Telomerase reverse transcriptase (RT) is present incompositions of the present invention at concentrations of at least fromabout 0.00005% w/w to about 0.001% w/w. In some embodiments, Telomerasereverse transcriptase (RT) is present in compositions of the presentinvention at concentrations of at least from about 0.0001% w/w to about0.001% w/w. In some embodiments, Telomerase reverse transcriptase (RT)is present in compositions of the present invention at concentrations ofmore than about 0.000006% w/w. In some embodiments, Telomerase reversetranscriptase (RT) is present in compositions of the present inventionat concentrations of more than about 0.00006% w/w. In some embodiments,Telomerase reverse transcriptase (RT) is present in compositions of thepresent invention at concentrations of more than about 0.0005% w/w. Insome embodiments, Telomerase reverse transcriptase (RT) is present incompositions of the present invention at concentrations of more thanabout 0.0006% w/w. In some embodiments, Telomerase reverse transcriptase(RT) is present in compositions of the present invention atconcentrations of more than about 0.006% w/w. In some embodiments,Telomerase reverse transcriptase (RT) is present in compositions of thepresent invention at concentrations of less than about 0.01% w/w. Insome embodiments, Telomerase reverse transcriptase (RT) is present incompositions of the present invention at concentrations of less thanabout 0.006% w/w. In some embodiments, Telomerase reverse transcriptase(RT) is present in compositions of the present invention atconcentrations of less than about 0.001% w/w. In some embodiments,Telomerase reverse transcriptase (RT) is present in compositions of thepresent invention at concentrations of less than about 0.0007% w/w. Insome embodiments, Telomerase reverse transcriptase (RT) is present incompositions of the present invention at concentrations of less thanabout 0.0006% w/w. In some embodiments, Telomerase reverse transcriptase(RT) is present in compositions of the present invention atconcentrations of less than about 0.0001% w/w. In some embodiments,Telomerase reverse transcriptase (RT) is present in compositions of thepresent invention at concentrations of less than about 0.00007% w/w. Insome embodiments, Telomerase reverse transcriptase (RT) is present incompositions of the present invention at concentrations of less thanabout 0.00006% w/w. In some embodiments, Telomerase reversetranscriptase (RT) is present in compositions of the present inventionat concentrations of less than about 0.00001% w/w. In some embodiments,Telomerase reverse transcriptase (RT) is present in compositions of thepresent invention at concentrations of less than about 0.000006% w/w.

In some embodiments, antibody to Telomerase RT is present incompositions of the present invention at concentrations of at least fromabout 0.000001% w/w to about 0.01% w/w. In some embodiments, antibody toTelomerase RT is present in compositions of the present invention atconcentrations of at least from about 0.000005% w/w to about 0.005% w/w.In some embodiments, antibody to Telomerase RT is present incompositions of the present invention at concentrations of at least fromabout 0.00001% w/w to about 0.001% w/w. In some embodiments, antibody toTelomerase RT is present in compositions of the present invention atconcentrations of at least from about 0.00005% w/w to about 0.001% w/w.In some embodiments, antibody to Telomerase RT is present incompositions of the present invention at concentrations of at least fromabout 0.0001% w/w to about 0.001% w/w. In some embodiments, antibody toTelomerase RT is present in compositions of the present invention atconcentrations of more than about 0.000001% w/w. In some embodiments,antibody to Telomerase RT is present in compositions of the presentinvention at concentrations of more than about 0.000006% w/w. In someembodiments, antibody to Telomerase RT is present in compositions of thepresent invention at concentrations of more than about 0.00001% w/w. Insome embodiments, antibody to Telomerase RT is present in compositionsof the present invention at concentrations of more than about 0.00005%w/w. In some embodiments, antibody to Telomerase RT is present incompositions of the present invention at concentrations of more thanabout 0.00006% w/w. In some embodiments, antibody to Telomerase RT ispresent in compositions of the present invention at concentrations ofmore than about 0.0001% w/w. In some embodiments, antibody to TelomeraseRT is present in compositions of the present invention at concentrationsof more than about 0.0006% w/w. In some embodiments, antibody toTelomerase RT is present in compositions of the present invention atconcentrations of less than about 0.01% w/w. In some embodiments,antibody to Telomerase RT is present in compositions of the presentinvention at concentrations of less than about 0.006% w/w. In someembodiments, antibody to Telomerase RT is present in compositions of thepresent invention at concentrations of less than 0.003% w/w. In someembodiments, antibody to Telomerase RT is present in compositions of thepresent invention at concentrations of less than about 0.001% w/w. Insome embodiments, antibody to Telomerase RT is present in compositionsof the present invention at concentrations of less than about 0.0007%w/w. In some embodiments, antibody to Telomerase RT is present incompositions of the present invention at concentrations of less thanabout 0.0006% w/w. In some embodiments, antibody to Telomerase RT ispresent in compositions of the present invention at concentrations ofless than about 0.0001% w/w. In some embodiments, antibody to TelomeraseRT is present in compositions of the present invention at concentrationsof less than about 0.00006% w/w. In some embodiments, antibody toTelomerase RT is present in compositions of the present invention atconcentrations of less than about 0.00001% w/w. In some embodiments,antibody to Telomerase RT is present in compositions of the presentinvention at concentrations of less than about 0.000007% w/w. In someembodiments, antibody to Telomerase RT is present in compositions of thepresent invention at concentrations of less than about 0.000006% w/w. Insome embodiments, antibody to Telomerase RT is present in compositionsof the present invention at concentrations of less than about 0.000001%w/w.

In some embodiments, Epidermal Growth Factor is present in compositionsof the present invention at concentrations of at least from about0.000001% w/w to about 0.001% w/w. In some embodiments, Epidermal GrowthFactor is present in compositions of the present invention atconcentrations of at least from about 0.000001% w/w to about 0.0005%w/w. In some embodiments, Epidermal Growth Factor is present incompositions of the present invention at concentrations of at least fromabout 0.000001% w/w to about 0.0001% w/w. In some embodiments, EpidermalGrowth Factor is present in compositions of the present invention atconcentrations of at least from about at least from about 0.00001% w/wto about 0.005% w/w. In some embodiments, Epidermal Growth Factor ispresent in compositions of the present invention at concentrations of atleast about 0.000001% w/w. In some embodiments, Epidermal Growth Factoris present in compositions of the present invention at concentrations ofat least about 0.0000015% w/w. In some embodiments, Epidermal GrowthFactor is present in compositions of the present invention atconcentrations of at least about 0.0000065% w/w. In some embodiments,Epidermal Growth Factor is present in compositions of the presentinvention at concentrations of at least about 0.000015% w/w. In someembodiments, Epidermal Growth Factor is present in compositions of thepresent invention at concentrations of at least about 0.000065% w/w. Insome embodiments, Epidermal Growth Factor is present in compositions ofthe present invention at concentrations of at least about 0.00015% w/w.In some embodiments, Epidermal Growth Factor is present in compositionsof the present invention at concentrations of at least about 0.00065%w/w. In some embodiments, Epidermal Growth Factor is present incompositions of the present invention at concentrations of at leastabout 0.001% w/w. In some embodiments, Epidermal Growth Factor ispresent in compositions of the present invention at concentrations ofless than about 0.001% w/w. In some embodiments, Epidermal Growth Factoris present in compositions of the present invention at concentrations ofless than about 0.00065% w/w. In some embodiments, Epidermal GrowthFactor is present in compositions of the present invention atconcentrations of less than about 0.0005% w/w. In some embodiments,Epidermal Growth Factor is present in compositions of the presentinvention at concentrations of less than about 0.00015% w/w. In someembodiments, Epidermal Growth Factor is present in compositions of thepresent invention at concentrations of less than about 0.000065% w/w. Insome embodiments, Epidermal Growth Factor is present in compositions ofthe present invention at concentrations of less than about 0.000015 w/w.

In some embodiments, Vascular Endothelial Growth Factor is present incompositions of the present invention at concentrations of at least fromabout 0.000001% w/w to about 0.001% w/w. In some embodiments, VascularEndothelial Growth Factor is present in compositions of the presentinvention at concentrations of at least from about 0.000001% w/w toabout 0.0005% w/w. In some embodiments, Vascular Endothelial GrowthFactor is present in compositions of the present invention atconcentrations of at least from about 0.000001% w/w to about 0.0001%w/w. In some embodiments, Vascular Endothelial Growth Factor is presentin compositions of the present invention at concentrations of at leastfrom about 0.000001% w/w to about 0.001% w/w. In some embodiments,Vascular Endothelial Growth Factor is present in compositions of thepresent invention at concentrations of at least about 0.000001% w/w. Insome embodiments, Vascular Endothelial Growth Factor is present incompositions of the present invention at concentrations of at leastabout 0.0000015% w/w. In some embodiments, Vascular Endothelial GrowthFactor is present in compositions of the present invention atconcentrations of at least about 0.0000065% w/w. In some embodiments,Vascular Endothelial Growth Factor is present in compositions of thepresent invention at concentrations of at least about 0.00001% w/w. Insome embodiments, Vascular Endothelial Growth Factor is present incompositions of the present invention at concentrations of at leastabout 0.000015% w/w. In some embodiments, Vascular Endothelial GrowthFactor is present in compositions of the present invention atconcentrations of at least about 0.00006% w/w. In some embodiments,Vascular Endothelial Growth Factor is present in compositions of thepresent invention at concentrations of at least about 0.000065% w/w. Insome embodiments, Vascular Endothelial Growth Factor is present incompositions of the present invention at concentrations of at leastabout 0.0001% w/w. In some embodiments, Vascular Endothelial GrowthFactor is present in compositions of the present invention atconcentrations of at least about 0.00015% w/w. In some embodiments,Vascular Endothelial Growth Factor is present in compositions of thepresent invention at concentrations of at least about 0.0006% w/w. Insome embodiments, Vascular Endothelial Growth Factor is present incompositions of the present invention at concentrations of at leastabout 0.00065% w/w. In some embodiments, Vascular Endothelial GrowthFactor is present in compositions of the present invention atconcentrations of at least about 0.001% w/w. In some embodiments,Vascular Endothelial Growth Factor is present in compositions of thepresent invention at concentrations of less than about 0.001% w/w. Insome embodiments, Vascular Endothelial Growth Factor is present incompositions of the present invention at concentrations of less thanabout 0.0007% w/w. In some embodiments, Vascular Endothelial GrowthFactor is present in compositions of the present invention atconcentrations of less than about 0.00065% w/w. In some embodiments,Vascular Endothelial Growth Factor is present in compositions of thepresent invention at concentrations of less than about 0.0002% w/w. Insome embodiments, Vascular Endothelial Growth Factor is present incompositions of the present invention at concentrations of less thanabout 0.00015% w/w. In some embodiments, Vascular Endothelial GrowthFactor is present in compositions of the present invention atconcentrations of less than about 0.000065% w/w. In some embodiments,Vascular Endothelial Growth Factor is present in compositions of thepresent invention at concentrations of less than about 0.000015% w/w. Insome embodiments, Vascular Endothelial Growth Factor is present incompositions of the present invention at concentrations of less thanabout 0.000007% w/w. In some embodiments, Vascular Endothelial GrowthFactor is present in compositions of the present invention atconcentrations of less than about 0.000001% w/w.

In some embodiments of the invention, a Fibroblast Growth Factor ispresent in the compositions of the present invention at concentrationsof at least from about 0.000001% w/w to about 0.01% w/w. In someembodiments of the invention, a Fibroblast Growth Factor is present inthe compositions of the present invention at concentrations of at leastfrom about 0.000001% w/w to about 0.001% w/w. In some embodiments of theinvention, a Fibroblast Growth Factor is present in the compositions ofthe present invention at concentrations of at least from about 0.000001%w/w to about 0.0001% w/w. In some embodiments of the invention, aFibroblast Growth Factor is present in the compositions of the presentinvention at concentrations of at least about 0.000001% w/w. In someembodiments of the invention, a Fibroblast Growth Factor is present inthe compositions of the present invention at concentrations of at leastabout 0.000002% w/w. In some embodiments of the invention, a FibroblastGrowth Factor is present in the compositions of the present invention atconcentrations of at least about 0.000003% w/w. In some embodiments ofthe invention, a Fibroblast Growth Factor is present in the compositionsof the present invention at concentrations of at least about 0.000004%w/w. In some embodiments of the invention, a Fibroblast Growth Factor ispresent in the compositions of the present invention at concentrationsof at least about 0.000005% w/w. In some embodiments of the invention, aFibroblast Growth Factor is present in the compositions of the presentinvention at concentrations of at least about 0.000006% w/w. In someembodiments of the invention, a Fibroblast Growth Factor is present inthe compositions of the present invention at concentrations of at leastabout 0.00001% w/w. In some embodiments of the invention, a FibroblastGrowth Factor is present in the compositions of the present invention atconcentrations of at least about 0.00002% w/w. In some embodiments ofthe invention, a Fibroblast Growth Factor is present in the compositionsof the present invention at concentrations of at least about 0.00003%w/w. In some embodiments of the invention, a Fibroblast Growth Factor ispresent in the compositions of the present invention at concentrationsof at least about 0.00004% w/w. In some embodiments of the invention, aFibroblast Growth Factor is present in the compositions of the presentinvention at concentrations of at least about 0.00005% w/w. In someembodiments of the invention, a Fibroblast Growth Factor is present inthe compositions of the present invention at concentrations of at leastabout 0.00006% w/w. In some embodiments of the invention, a FibroblastGrowth Factor is present in the compositions of the present invention atconcentrations of at least about 0.00007% w/w. In some embodiments ofthe invention, a Fibroblast Growth Factor is present in the compositionsof the present invention at concentrations of at least about 0.0001%w/w. In some embodiments of the invention, a Fibroblast Growth Factor ispresent in the compositions of the present invention at concentrationsof at least about 0.0003% w/w. In some embodiments of the invention, aFibroblast Growth Factor is present in the compositions of the presentinvention at concentrations of at least about 0.0006% w/w. In someembodiments of the invention, a Fibroblast Growth Factor is present inthe compositions of the present invention at concentrations of at leastabout 0.001% w/w. In some embodiments of the invention, a FibroblastGrowth Factor is present in the compositions at concentrations less thanabout 0.01% w/w. In some embodiments of the invention, a FibroblastGrowth Factor is present in the compositions at concentrations less thanabout 0.006% w/w. In some embodiments of the invention, a FibroblastGrowth Factor is present in the compositions at concentrations less thanabout 0.001% w/w. In some embodiments of the invention, a FibroblastGrowth Factor is present in the compositions at concentrations less thanabout 0.0007% w/w. In some embodiments of the invention, a FibroblastGrowth Factor is present in the compositions at concentrations less thanabout 0.00065% w/w. In some embodiments of the invention, a FibroblastGrowth Factor is present in the compositions at concentrations less thanabout 0.0006% w/w. 0. In some embodiments of the invention, a FibroblastGrowth Factor is present in the compositions at concentrations less thanabout 0.00010% w/w. In some embodiments of the invention, a FibroblastGrowth Factor is present in the compositions at concentrations less thanabout 0.00007% w/w. In some embodiments of the invention, a FibroblastGrowth Factor is present in the compositions at concentrations less thanabout 0.00006% w/w In some embodiments of the invention, a FibroblastGrowth Factor is present in the compositions at concentrations less thanabout 0.00001% w/w. In some embodiments of the invention, a FibroblastGrowth Factor is present in the compositions at concentrations less thanabout 0.000007% w/w. In some embodiments of the invention, a FibroblastGrowth Factor is present in the compositions at concentrations less thanabout 0.000006% w/w. In some embodiments of the invention, a FibroblastGrowth Factor is present in the compositions at concentrations less thanabout 0.000001% w/w. In some embodiments of the invention, more than oneFibroblast Growth Factor is present in the compositions of the presentinvention, each independently at concentrations of at least from about0.000001% w/w to about 0.01% w/w. In some embodiments of the invention,more than one Fibroblast Growth Factor is present in the compositions ofthe present invention, each independently at concentrations of at leastfrom about 0.000001% w/w to about 0.001% w/w. In some embodiments of theinvention, more than one Fibroblast Growth Factor is present in thecompositions of the present invention, each independently atconcentrations of at least from about 0.000001% w/w to about 0.0001%w/w. In some embodiments of the invention, more than one FibroblastGrowth Factor is present in the compositions of the present invention,each independently at concentrations of at least about 0.000001% w/w. Insome embodiments of the invention, more than one Fibroblast GrowthFactor is present in the compositions of the present invention, eachindependently at concentrations of at least about 0.000005% w/w. In someembodiments of the invention, more than one Fibroblast Growth Factor ispresent in the compositions of the present invention, each independentlyat concentrations of at least about 0.00001% w/w. In some embodiments ofthe invention, more than one Fibroblast Growth Factor is present in thecompositions of the present invention, each independently atconcentrations of at least about 0.00005% w/w. In some embodiments ofthe invention, more than one Fibroblast Growth Factor is present in thecompositions of the present invention, each independently atconcentrations of at least about 0.00006% w/w. In some embodiments ofthe invention, more than one Fibroblast Growth Factor is present in thecompositions of the present invention, each independently atconcentrations of at least about 0.0001% w/w. In some embodiments of theinvention, more than one Fibroblast Growth Factor is present in thecompositions of the present invention, each independently atconcentrations of at least about 0.00015% w/w. In some embodiments ofthe invention, more than one Fibroblast Growth Factor is present in thecompositions, each independently at concentrations less than about 0.01%w/w. In some embodiments of the invention, more than one FibroblastGrowth Factor is present in the compositions, each independently atconcentrations less than about 0.007% w/w. In some embodiments of theinvention, more than one Fibroblast Growth Factor is present in thecompositions, each independently at concentrations less than about0.006% w/w. In some embodiments of the invention, more than oneFibroblast Growth Factor is present in the compositions, eachindependently at concentrations less than about 0.001% w/w. In someembodiments of the invention, more than one Fibroblast Growth Factor ispresent in the compositions, each independently at concentrations lessthan about 0.0007% w/w. In some embodiments of the invention, more thanone Fibroblast Growth Factor is present in the compositions, eachindependently at concentrations less than about 0.0006% w/w. In someembodiments of the invention, more than one Fibroblast Growth Factor ispresent in the compositions, each independently at concentrations lessthan about 0.00010% w/w. In some embodiments of the invention, more thanone Fibroblast Growth Factor is present in the compositions, eachindependently at concentrations less than about 0.000065% w/w. In someembodiments of the invention, more than one Fibroblast Growth Factor ispresent in the compositions, each independently at concentrations lessthan about 0.000001% w/w.

In some embodiments, Keratinocyte Growth Factor-1 is present in thecompositions of the present invention at concentrations of at least fromabout 0.000001% w/w to about 0.01% w/w. In some embodiments,Keratinocyte Growth Factor-1 is present in the compositions of thepresent invention at concentrations of at least from about 0.000001% w/wto about 0.001% w/w. In some embodiments, Keratinocyte Growth Factor-1is present in the compositions of the present invention atconcentrations of at least from about 0.000001% w/w to about 0.0001%w/w. In some embodiments, Keratinocyte Growth Factor-1 is present in thecompositions of the present invention at concentrations of at leastabout 0.000001% w/w. In some embodiments, Keratinocyte Growth Factor-1is present in the compositions of the present invention atconcentrations of at least about 0.000006% w/w. In some embodiments,Keratinocyte Growth Factor-1 is present in the compositions of thepresent invention at concentrations of at least about 0.00001% w/w. Insome embodiments, Keratinocyte Growth Factor-1 is present in thecompositions of the present invention at concentrations of at leastabout 0.00005%; w/w. In some embodiments, Keratinocyte Growth Factor-1is present in the compositions of the present invention atconcentrations of at least about 0.00006% w/w. In some embodiments,Keratinocyte Growth Factor-1 is present in the compositions of thepresent invention at concentrations of at least about 0.0001% w/w. Insome embodiments, Keratinocyte Growth Factor-1 is present in thecompositions of the present invention at concentrations of at leastabout 0.0006% w/w. In some embodiments, Keratinocyte Growth Factor-1 ispresent in the compositions of the present invention at concentrationsof at least about 0.001% w/w. In other embodiments, Keratinocyte GrowthFactor-1 is present in the compositions at concentrations less thanabout 0.01% w/w. In other embodiments, Keratinocyte Growth Factor-1 ispresent in the compositions at concentrations less than about 0.006%w/w. In other embodiments, Keratinocyte Growth Factor-1 is present inthe compositions at concentrations less than about 0.001% w/w. In otherembodiments, Keratinocyte Growth Factor-1 is present in the compositionsat concentrations less than about 0.0007% w/w. In other embodiments,Keratinocyte Growth Factor-1 is present in the compositions atconcentrations less than about 0.0006% w/w. In other embodiments,Keratinocyte Growth Factor-1 is present in the compositions atconcentrations less than about 0.00010% w/w. In other embodiments,Keratinocyte Growth Factor-1 is present in the compositions atconcentrations less than about 0.00007% w/w. In other embodiments,Keratinocyte Growth Factor-1 is present in the compositions atconcentrations less than about 0.00006% w/w. In other embodiments,Keratinocyte Growth Factor-1 is present in the compositions atconcentrations less than about 0.00001% w/w. In other embodiments,Keratinocyte Growth Factor-1 is present in the compositions atconcentrations less than about 0.000006% w/w.

In some embodiments, Keratinocyte Growth Factor-2 is present in thecompositions of the present invention at concentrations of at least fromabout 0.000001% w/w to about 0.01% w/w. In some embodiments,Keratinocyte Growth Factor-2 is present in the compositions of thepresent invention at concentrations of at least from about 0.000001% w/wto about 0.001% w/w. In some embodiments, Keratinocyte Growth Factor-2is present in the compositions of the present invention atconcentrations of at least from about 0.000001% w/w to about 0.0001%w/w. In other embodiments, Keratinocyte Growth Factor-2 is present inthe compositions of the present invention at concentrations of at leastabout 0.000001% w/w. In other embodiments, Keratinocyte Growth Factor-2is present in the compositions of the present invention atconcentrations of at least about 0.000006% w/w. In other embodiments,Keratinocyte Growth Factor-2 is present in the compositions of thepresent invention at concentrations of at least about 0.00001% w/w. Inother embodiments, Keratinocyte Growth Factor-2 is present in thecompositions of the present invention at concentrations of at leastabout 0.00005% w/w. In other embodiments, Keratinocyte Growth Factor-2is present in the compositions of the present invention atconcentrations of at least about 0.00006% w/w. In other embodiments,Keratinocyte Growth Factor-2 is present in the compositions of thepresent invention at concentrations of at least about 0.0001% w/w. Inother embodiments, Keratinocyte Growth Factor-2 is present in thecompositions of the present invention at concentrations of at leastabout 0.0005% w/w. In other embodiments, Keratinocyte Growth Factor-2 ispresent in the compositions of the present invention at concentrationsof at least about 0.001% w/w. In yet other embodiments, KeratinocyteGrowth Factor-2 is present in the compositions at concentrations lessthan about 0.01% w/w. In yet other embodiments, Keratinocyte GrowthFactor-2 is present in the compositions at concentrations less thanabout 0.006% w/w. In yet other embodiments, Keratinocyte Growth Factor-2is present in the compositions at concentrations less than about 0.001%w/w. In yet other embodiments, Keratinocyte Growth Factor-2 is presentin the compositions at concentrations less than about 0.0007% w/w. Inyet other embodiments, Keratinocyte Growth Factor-2 is present in thecompositions at concentrations less than about 0.0006% w/w. In yet otherembodiments, Keratinocyte Growth Factor-2 is present in the compositionsat concentrations less than about 0.00010% w/w. In yet otherembodiments, Keratinocyte Growth Factor-2 is present in the compositionsat concentrations less than about 0.00007% w/w. In yet otherembodiments, Keratinocyte Growth Factor-2 is present in the compositionsat concentrations less than about 0.00006% w/w. In yet otherembodiments, Keratinocyte Growth Factor-2 is present in the compositionsat concentrations less than about 0.00001% w/w. In yet otherembodiments, Keratinocyte Growth Factor-2 is present in the compositionsat concentrations less than about 0.000007% w/w. In yet otherembodiments, Keratinocyte Growth Factor-2 is present in the compositionsat concentrations less than about 0.000001% w/w.

In some embodiments, Transforming Growth Factor-β1 is present incompositions of the present invention at concentrations of at least fromabout 0.000001% w/w to about 0.001% w/w. In some embodiments,Transforming Growth Factor-β1 is present in compositions of the presentinvention at concentrations of at least from about 0.000001% w/w toabout 0.0005% w/w. In some embodiments, Transforming Growth Factor-β1 ispresent in compositions of the present invention at concentrations of atleast from about 0.000001% w/w to about 0.0001% w/w. In someembodiments, Transforming Growth Factor-β1 is present in compositions ofthe present invention at concentrations of at least from about 0.000001%w/w to about 0.0001% w/w. In some embodiments, Transforming GrowthFactor-β1 is present in compositions of the present invention atconcentrations of at least about 0.000001% w/w. In some embodiments,Transforming Growth Factor-β1 is present in compositions of the presentinvention at concentrations of at least about 0.000005% w/w. In someembodiments, Transforming Growth Factor-β1 is present in compositions ofthe present invention at concentrations of at least about 0.00001% w/w.In some embodiments, Transforming Growth Factor-β1 is present incompositions of the present invention at concentrations of at leastabout 0.000015% w/w. In some embodiments, Transforming Growth Factor-β1is present in compositions of the present invention at concentrations ofat least about 0.00002% w/w. In some embodiments, Transforming GrowthFactor-β1 is present in compositions of the present invention atconcentrations of at least about 0.00007% w/w. In some embodiments,Transforming Growth Factor-β1 is present in compositions of the presentinvention at concentrations of at least about 0.0002% w/w. In someembodiments, Transforming Growth Factor-β1 is present in compositions ofthe present invention at concentrations of at least about 0.0007% w/w.In some embodiments, Transforming Growth Factor-β1 is present incompositions of the present invention at concentrations of less thanabout 0.001% w/w. In some embodiments, Transforming Growth Factor-β1 ispresent in compositions of the present invention at concentrations ofless than about 0.00075% w/w. In some embodiments, Transforming GrowthFactor-β1 is present in compositions of the present invention atconcentrations of less than about 0.00025% w/w. In some embodiments,Transforming Growth Factor-β1 is present in compositions of the presentinvention at concentrations of less than about 0.0002% w/w. In someembodiments, Transforming Growth Factor-β1 is present in compositions ofthe present invention at concentrations of less than about 0.000075%w/w. In some embodiments, Transforming Growth Factor-β1 is present incompositions of the present invention at concentrations of less thanabout 0.000025% w/w. In some embodiments, Transforming Growth Factor-β1is present in compositions of the present invention at concentrations ofless than about 0.00002% w/w. In some embodiments, Transforming GrowthFactor-β1 is present in compositions of the present invention atconcentrations of less than about 0.00001% w/w.

In some embodiments, a myristoylated peptide is present in thecompositions of the invention at concentrations of at least from about0.001% w/w to about 2.0% w/w. In some embodiments, a myristoylatedpeptide is present in the compositions of the invention atconcentrations of at least from about 0.01% w/w to about 2.0% w/w. Insome embodiments, a myristoylated peptide is present in the compositionsof the invention at concentrations of at least from about 0.05% w/w toabout 2.0% w/w. In some embodiments, a myristoylated peptide is presentin the compositions of the invention at concentrations of at least fromabout 0.01% w/w to about 2.0% w/w. In some embodiments, a myristoylatedpeptide is present in the compositions of the invention atconcentrations of at least about 0.001% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations of at least about 0.005% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations of at least about 0.01% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations of at least about 0.04% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations of at least about 0.05% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations of at least about 0.10% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations of at least about 0.40% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations of at least about 0.50% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations of at least about 1.00% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations of at least about 1.40% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations of at least about 1.50% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations of at least about 2.00% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations less than about 2.00% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations less than about 1.50% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations less than about 1.00% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations less than about 0.75% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations less than about 0.50% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations less than about 0.10% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations less than about 0.05% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations less than about 0.001% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations less than about 0.0005% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations less than about 0.0001% w/w. In some embodiments, morethan one myristoylated peptide is present in the compositions of theinventions, each independently at concentrations of at least from about0.001% w/w to about 2.0% w/w. In some embodiments, more than onemyristoylated peptide is present in the compositions of the inventions,each independently at concentrations of at least from about 0.01% w/w toabout 2.0% w/w. In some embodiments, more than one myristoylated peptideis present in the compositions of the inventions, each independently atconcentrations of at least from about 0.05% w/w to about 2.0% w/w. Insome embodiments, more than one myristoylated peptide is present in thecompositions of the inventions, each independently at concentrations ofat least from about 0.01% w/w to about 2.0% w/w. In some embodiments,more than one myristoylated peptide is present in the compositions ofthe invention, each independently at concentrations of at least about0.001% w/w. In some embodiments, more than one myristoylated peptide ispresent in the compositions of the invention, each independently atconcentrations of at least about 0.005% w/w. In some embodiments, morethan one myristoylated peptide is present in the compositions of theinvention, each independently at concentrations of at least about 0.01%w/w. In some embodiments, more than one myristoylated peptide is presentin the compositions of the invention, each independently atconcentrations of at least about 0.04% w/w. In some embodiments, morethan one myristoylated peptide is present in the compositions of theinvention, each independently at concentrations of at least about 0.05%w/w. In some embodiments, more than one myristoylated peptide is presentin the compositions of the invention, each independently atconcentrations of at least about 0.10% w/w. In some embodiments, morethan one myristoylated peptide is present in the compositions of theinvention, each independently at concentrations of at least about 0.20%w/w. In some embodiments, more than one myristoylated peptide is presentin the compositions of the invention, each independently atconcentrations of at least about 0.40% w/w In some embodiments, morethan one myristoylated peptide is present in the compositions of theinvention, each independently at concentrations of at least about 0.50%w/w. In some embodiments, more than one myristoylated peptide is presentin the compositions of the invention, each independently atconcentrations of at least about 1.00% w/w. In some embodiments, morethan one myristoylated peptide is present in the compositions of theinvention, each independently at concentrations of at least about 1.50%w/w. In some embodiments, more than one myristoylated peptide is presentin the compositions of the invention, each independently atconcentrations of at least about 2.00% w/w. In some embodiments, morethan one myristoylated peptide may be present in the compositions of theinvention, each independently at concentrations less than about 2.00%w/w. In some embodiments, more than one myristoylated peptide may bepresent in the compositions of the invention, each independently atconcentrations less than about 1.50% w/w. In some embodiments, more thanone myristoylated peptide may be present in the compositions of theinvention, each independently at concentrations less than about 1.00%w/w. In some embodiments, more than one myristoylated peptide may bepresent in the compositions of the invention, each independently atconcentrations less than about 0.60% w/w. In some embodiments, more thanone myristoylated peptide may be present in the compositions of theinvention, each independently at concentrations less than about 0.50%w/w. In some embodiments, more than one myristoylated peptide may bepresent in the compositions of the invention, each independently atconcentrations less than about 0.10% w/w. In some embodiments, more thanone myristoylated peptide may be present in the compositions of theinvention, each independently at concentrations less than about 0.05%w/w. In some embodiments, more than one myristoylated peptide may bepresent in the compositions of the invention, each independently atconcentrations less than about 0.001% w/w. In some embodiments, morethan one myristoylated peptide may be present in the compositions of theinvention, each independently at concentrations less than about 0.0001%w/w.

In some embodiments, a palmitoylated peptide is present in thecompositions of the present invention at concentrations of at least fromabout 0.50% w/w to about 6.00% w/w. In some embodiments, a palmitoylatedpeptide is present in the compositions of the invention atconcentrations of at least about 0.50% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of at least about 1.00% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of at least about 1.50% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of at least about 2.00% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of at least about 2.50% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of at least about 3.00% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of at least about 3.50% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of at least about 4.00% w/w In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of at least about 4.50% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of at least about 5.00% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of at least about 5.50% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of at least about 6.00% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of less than about 6.00% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of less than about 5.50% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of less than about 5.00% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of less than about 4.50% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of less than about 4.00% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of less than about 3.50% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of less than about 3.00% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of less than about 2.50% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of less than about 2.00% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of less than about 1.50% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of less than about 1.00% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of less than about 0.50% w/w. In some embodiments, morethan one palmitoylated peptide is present in the compositions of theinvention each independently at concentrations of at least about 0.50%w/w. In some embodiments, more than one palmitoylated peptide is presentin the compositions of the invention each independently atconcentrations of at least about 1.00% w/w. In some embodiments, morethan one palmitoylated peptide is present in the compositions of theinvention each independently at concentrations of at least about 1.50%w/w. In some embodiments, more than one palmitoylated peptide is presentin the compositions of the invention each independently atconcentrations of at least about 2.00% w/w. In some embodiments, morethan one palmitoylated peptide is present in the compositions of theinvention each independently at concentrations of at least about 2.50%w/w. In some embodiments, more than one palmitoylated peptide is presentin the compositions of the invention each independently atconcentrations of at least about 3.00% w/w. In some embodiments, morethan one palmitoylated peptide is present in the compositions of theinvention each independently at concentrations of at least about 3.50%w/w. In some embodiments, more than one palmitoylated peptide is presentin the compositions of the invention each independently atconcentrations of at least about 4.00% w/w. In some embodiments, morethan one palmitoylated peptide is present in the compositions of theinvention each independently at concentrations of at least about 4.50%w/w. In some embodiments, more than one palmitoylated peptide is presentin the compositions of the invention each independently atconcentrations of at least about 5.00% w/w. In some embodiments, morethan one palmitoylated peptide is present in the compositions of theinvention each independently at concentrations of at least about 5.50%w/w. In some embodiments, more than one palmitoylated peptide is presentin the compositions of the invention each independently atconcentrations of at least about 6.00% w/w. In some embodiments, morethan one palmitoylated peptide is present in the compositions of theinvention, each independently at concentrations of less than about 6.00%w/w. In some embodiments, more than one palmitoylated peptide is presentin the compositions of the invention, each independently atconcentrations of less than about 5.50% w/w. In some embodiments, morethan one palmitoylated peptide is present in the compositions of theinvention, each independently at concentrations of less than about 5.00%w/w. In some embodiments, more than one palmitoylated peptide is presentin the compositions of the invention, each independently atconcentrations of less than about 4.50% w/w. In some embodiments, morethan one palmitoylated peptide is present in the compositions of theinvention, each independently at concentrations of less than about 4.00%w/w. In some embodiments, more than one palmitoylated peptide is presentin the compositions of the invention, each independently atconcentrations of less than about 3.50% w/w. In some embodiments, morethan one palmitoylated peptide is present in the compositions of theinvention, each independently at concentrations of less than about 3.00%w/w. 2. In some embodiments, more than one palmitoylated peptide ispresent in the compositions of the invention, each independently atconcentrations of less than about 2.50% w/w. In some embodiments, morethan one palmitoylated peptide is present in the compositions of theinvention, each independently at concentrations of less than about 2.00%w/w. In some embodiments, more than one palmitoylated peptide is presentin the compositions of the invention, each independently atconcentrations of less than about 1.50% w/w. In some embodiments, morethan one palmitoylated peptide is present in the compositions of theinvention, each independently at concentrations of less than about 1.00%w/w. In some embodiments, more than one palmitoylated peptide is presentin the compositions of the invention, each independently atconcentrations of less than about 0.50% w/w.

In some embodiments, one or more antioxidants are present in thecompositions of the invention, each independently at concentrationspresent in the compositions of the invention at concentrations of atleast from about 0.001% w/w to about 2.0% w/w. In some embodiments, oneor more antioxidants are present in the compositions of the invention,each independently at concentrations present in the compositions of theinvention at concentrations of at least from about 0.01% w/w to about2.0% w/w. In some embodiments, one or more antioxidants are present inthe compositions of the invention, each independently at concentrationspresent in the compositions of the invention at concentrations of atleast from about 0.05% w/w to about 2.0% w/w. In some embodiments, oneor more antioxidants are present in the compositions of the invention,each independently at concentrations present in the compositions of theinvention at concentrations of at least from about 0.01% w/w to about2.0% w/w. In some embodiments, one or more antioxidants are present inthe compositions of the invention, each independently at concentrationsof at least about 0.001% w/w. In some embodiments, one or moreantioxidants are present in the compositions of the invention, eachindependently at concentrations of at least about 0.005% w/w. In someembodiments, one or more antioxidants are present in the compositions ofthe invention, each independently at concentrations of at least about0.01% w/w. In some embodiments, one or more antioxidants are present inthe compositions of the invention, each independently at concentrationsof at least about 0.05% w/w. In some embodiments, one or moreantioxidants are present in the compositions of the invention, eachindependently at concentrations of at least about 0.10% w/w. In someembodiments, one or more antioxidants are present in the compositions ofthe invention, each independently at concentrations of at least about0.50% w/w. In some embodiments, one or more antioxidants are present inthe compositions of the invention, each independently at concentrationsof at least about 1.00% w/w. In some embodiments, one or moreantioxidants are present in the compositions of the invention, eachindependently at concentrations of at least about 1.50% w/w. In someembodiments, one or more antioxidants are present in the compositions ofthe invention, each independently at concentrations of at least about2.00% w/w. In some embodiments, one or more antioxidants are present inthe compositions of the invention, each independently at concentrationsless than about 2.00% w/w. In some embodiments, one or more antioxidantsare present in the compositions of the invention, each independently atconcentrations less than about 1.50% w/w. In some embodiments, one ormore antioxidants are present in the compositions of the invention, eachindependently at concentrations less than about 1.00% w/w. In someembodiments, one or more antioxidants are present in the compositions ofthe invention, each independently at concentrations less than about0.50% w/w. In some embodiments, one or more antioxidants are present inthe compositions of the invention, each independently at concentrationsless than about 0.10% w/w. In some embodiments, one or more antioxidantsare present in the compositions of the invention, each independently atconcentrations less than about 0.05% w/w. In some embodiments, one ormore antioxidants are present in the compositions of the invention, eachindependently at concentrations less than about 0.001% w/w. In someembodiments, one or more antioxidants are present in the compositions ofthe invention, each independently at concentrations less than about0.005% w/w. In some embodiments, one or more antioxidants are present inthe compositions of the invention, each independently at concentrationsless than about 0.0001% w/w.

In some embodiments, ubiquinone is present in the compositions of theinvention at concentrations present in the compositions of the inventionat concentrations of at least from about 0.001% w/w to about 2.0% w/w.In some embodiments, ubiquinone is present in the compositions of theinvention at concentrations present in the compositions of the inventionat concentrations of at least from about 0.01% w/w to about 2.0% w/w. Insome embodiments, ubiquinone is present in the compositions of theinvention at concentrations present in the compositions of the inventionat concentrations of at least from about 0.05% w/w to about 2.0% w/w. Insome embodiments, ubiquinone is present in the compositions of theinvention at concentrations present in the compositions of the inventionat concentrations of at least from about 0.01% w/w to about 2.0% w/w. Insome embodiments, ubiquinone is present in the compositions of theinvention, at concentrations of at least about 0.001% w/w. In someembodiments, ubiquinone is present in the compositions of the invention,at concentrations of at least about 0.005% w/w. In some embodiments,ubiquinone is present in the compositions of the invention, atconcentrations of at least about 0.01% w/w. In some embodiments,ubiquinone is present in the compositions of the invention, atconcentrations of at least about 0.05% w/w. In some embodiments,ubiquinone is present in the compositions of the invention, atconcentrations of at least about 0.10% w/w. In some embodiments,ubiquinone is present in the compositions of the invention, atconcentrations of at least about 0.20% w/w. In some embodiments,ubiquinone is present in the compositions of the invention, atconcentrations of at least about 0.30% w/w. In some embodiments,ubiquinone is present in the compositions of the invention, atconcentrations of at least about 0.40% w/w. In some embodiments,ubiquinone is present in the compositions of the invention, atconcentrations of at least about 0.50% w/w. In some embodiments,ubiquinone is present in the compositions of the invention, atconcentrations of at least about 0.60% w/w. In some embodiments,ubiquinone is present in the compositions of the invention, atconcentrations of at least about 0.70% w/w. In some embodiments,ubiquinone is present in the compositions of the invention, atconcentrations of at least about 0.80% w/w. In some embodiments,ubiquinone is present in the compositions of the invention, atconcentrations of at least about 1.00% w/w. In some embodiments,ubiquinone is present in the compositions of the invention, atconcentrations of at least about 1.50% w/w. In some embodiments,ubiquinone is present in the compositions of the invention, atconcentrations of at least about 2.00% w/w. In some embodiments,ubiquinone is present in the compositions of the invention atconcentrations less than about 2.00% w/w. In some embodiments,ubiquinone is present in the compositions of the invention atconcentrations less than about 1.50% w/w. In some embodiments,ubiquinone is present in the compositions of the invention atconcentrations less than about 1.00% w/w. In some embodiments,ubiquinone is present in the compositions of the invention atconcentrations less than about 0.60% w/w. In some embodiments,ubiquinone is present in the compositions of the invention atconcentrations less than about 0.50% w/w. In some embodiments,ubiquinone is present in the compositions of the invention atconcentrations less than about 0.40% w/w. In some embodiments,ubiquinone is present in the compositions of the invention atconcentrations less than about 0.30% w/w. In some embodiments,ubiquinone is present in the compositions of the invention atconcentrations less than about 0.20% w/w. In some embodiments,ubiquinone is present in the compositions of the invention atconcentrations less than about 0.10% w/w. In some embodiments,ubiquinone is present in the compositions of the invention atconcentrations less than about 0.05% w/w. In some embodiments,ubiquinone is present in the compositions of the invention atconcentrations less than about 0.001% w/w. In some embodiments,ubiquinone is present in the compositions of the invention atconcentrations less than about 0.005% w/w. In some embodiments,ubiquinone is present in the compositions of the invention atconcentrations less than about 0.0001% w/w.

In some embodiments, green tea extract is present in the compositions ofthe invention at concentrations present in the compositions of theinvention at concentrations of at least from about 0.001% w/w to about2.0% w/w. In some embodiments, green tea extract is present in thecompositions of the invention at concentrations present in thecompositions of the invention at concentrations of at least from about0.01% w/w to about 2.0% w/w. In some embodiments, green tea extract ispresent in the compositions of the invention at concentrations presentin the compositions of the invention at concentrations of at least fromabout 0.05% w/w to about 2.0% w/w. In some embodiments, green teaextract is present in the compositions of the invention atconcentrations present in the compositions of the invention atconcentrations of at least from about 0.01% w/w to about 2.0% w/w. Insome embodiments, green tea extract is present in the compositions ofthe invention, at concentrations of at least about 0.001% w/w. In someembodiments, green tea extract is present in the compositions of theinvention, at concentrations of at least about 0.005% w/w. In someembodiments, green tea extract is present in the compositions of theinvention, at concentrations of at least about 0.01% w/w. In someembodiments, green tea extract is present in the compositions of theinvention, at concentrations of at least about 0.05% w/w. In someembodiments, green tea extract is present in the compositions of theinvention, at concentrations of at least about 0.10% w/w. In someembodiments, green tea extract is present in the compositions of theinvention, at concentrations of at least about 0.50% w/w. In someembodiments, green tea extract is present in the compositions of theinvention, at concentrations of at least about 0.75% w/w. In someembodiments, green tea extract is present in the compositions of theinvention, at concentrations of at least about 1.00% w/w. In someembodiments, green tea extract is present in the compositions of theinvention, at concentrations of at least about 1.50% w/w. In someembodiments, green tea extract is present in the compositions of theinvention, at concentrations of at least about 2.00% w/w. In someembodiments, green tea extract is present in the compositions of theinvention at concentrations less than about 2.00% w/w. In someembodiments, green tea extract is present in the compositions of theinvention at concentrations less than about 1.50% w/w. In someembodiments, green tea extract is present in the compositions of theinvention at concentrations less than about 1.00% w/w. In someembodiments, green tea extract is present in the compositions of theinvention at concentrations less than about 0.70% w/w. In someembodiments, green tea extract is present in the compositions of theinvention at concentrations less than about 0.60% w/w. In someembodiments, green tea extract is present in the compositions of theinvention at concentrations less than about 0.50% w/w. In someembodiments, green tea extract is present in the compositions of theinvention at concentrations less than about 0.40% w/w. In someembodiments, green tea extract is present in the compositions of theinvention at concentrations less than about 0.30% w/w. In someembodiments, green tea extract is present in the compositions of theinvention at concentrations less than about 0.20% w/w. In someembodiments, green tea extract is present in the compositions of theinvention at concentrations less than about 0.10% w/w. In someembodiments, green tea extract is present in the compositions of theinvention at concentrations less than about 0.05% w/w. In someembodiments, green tea extract is present in the compositions of theinvention at concentrations less than about 0.001% w/w. In someembodiments, green tea extract is present in the compositions of theinvention at concentrations less than about 0.005% w/w. In someembodiments, green tea extract is present in the compositions of theinvention at concentrations less than about 0.0001% w/w.

In some embodiments of the invention, the compositions described hereinare applied topically to the skin of a human to reduce inflammation fromeither intrinsic or extrinsic sources. In other embodiments of theinvention, the compositions described herein are applied topically tothe skin of a human to reduce oxidative stress from either extrinsic orintrinsic sources. In other embodiments of the invention, thecompositions described herein are applied topically to the skin of ahuman to produce a skin brightening effect. In other embodiments of theinvention, the compositions described herein are applied topically tothe skin of a human to reduce fine lines and wrinkles in skin. In someother embodiments of the invention, the compositions described hereinare applied topically to the skin of a human to enhance elasticity ofskin. In other embodiments of the invention, the compositions describedherein are applied topically to the skin of a human to reduce theappearance of scarring and lesions of the skin due to extrinsic andintrinsic factors

INCORPORATION BY REFERENCE

All publications and patent applications mentioned in this specificationare herein incorporated by reference to the same extent as if eachindividual publication or patent application was specifically andindividually indicated to be incorporated by reference.

DETAILED DESCRIPTION OF THE INVENTION I. Skin Care Compositions

Compositions of the present invention are useful in helping to reducethe appearance of the signs of biological or environmentally-causedaging, including fine lines, wrinkles, age spots and reduced skinelasticity. In one aspect of the present invention relates totopically-applied cosmetic or dermatological compositions comprising (i)telomerase; (ii) a myristoylated peptide; and (iii) two specific growthfactors (an Epidermal Growth Factor and a Keratinocyte Growth Factor)Biological aging, also known as intrinsic aging or senescence, ismanifested as fine lines, wrinkles and deepening of facial expressionlines. Intrinsically-aged skin is thin and inelastic. Photodamage andother extrinsic causes of skin aging can be manifested in skin thatappears yellowed, blemished, mottled (i.e., in terms of pigmentation),coarsely wrinkled and furrowed. Extrinsically-aged skin can appearthickened, lax, rough and leathery. There has been and remains a needfor cosmeceutical products that better address both intrinsic andextrinsic causes of skin aging. The compositions of the presentinvention may be used to slow or prevent symptoms of aging skin.

At a physiological level, intrinsically-aged skin has changes in skinmatrix proteins, including collagen and elastin. Senescent skinfibroblasts produce lesser amounts of these proteins. Additionally, agedskin is characterized by increased levels of enzymes, such ascollagenase and matrix metalloproteinase (MMPs) that break down the skinmatrix. At a cellular level, the increased production of collagenase andMMPs and concomitant decrease in the rate of synthesis of collagen andelastin is a result of an altered pattern of gene expression. Moreparticularly, expression of genes that code for enzymes that break downthe skin matrix is increased, while expression of genes that code forthe synthesis of the matrix proteins themselves is decreased.

A. Skin Care Actives

In the compositions and methods described herein, a number of skin careactives are included.

Telomerase.

At a chromosomal level, the altered pattern of gene expression in thesenescent process is due in part to the activity of telomeres. Telomeresare structures on ends of chromosomes consisting of repetitive segmentsof DNA that regulate the replication of the chromosomes and thusregulate the process of cellular division. In humans, telomeres have therepetitive sequence TTAGGG. Some have described telomeres as “molecularswitches” that initiate the sequence of chromosomal replication andduplication.

Each time a cell divides, telomeres shorten by a small amount. Afterrepeated cell divisions, telomeres shortened past a critical thresholdare unable to initiate chromosomal replication. Cell division thusceases, causing the cell to become senescent. Recently an enzyme,telomerase, was identified and characterized which can “rebuild”telomeres, thus prolonging the viability of cells.

More specifically, telomerase comprises two distinct componentmolecules. The first component, designated TR, is Telomerase RNA. Thesecond protein component of telomerase is Telomerase ReverseTranscriptase (TRT), which reads the component RNA template (TR) tobuild the complementary DNA strand and thus directs the synthesis of therepeated TTAGGG sequences that form the telomere. It is in this mannerthat telomerase lengthens telomeres. The respective components of thehuman form are human Telomerase RNA (hTR) and human Telomerase ReverseTranscriptase (hTRT). These components, singly and in combination, areuseful skin care actives.

In one embodiment of the invention, the component of telomeraseincorporated in the compositions of the invention has an amino acidsequence with at least 90%, 95%, 98%, or 99% sequence homology to theamino acid sequence of a telomerase reverse transcriptase of an animal.In another embodiment of the invention, the component of telomeraseincorporated in the compositions of the invention has an amino acidsequence with at least 90%, 95%, 98%, or 99% sequence homology to theamino acid sequence of a telomerase RNA of any animal. In anotherembodiment of the present invention the component of telomeraseincorporated in the compositions of the invention has an amino acidsequence with at least 90%, 95%, 98%, or 99% sequence homology to theamino acid sequence of human telomerase RNA (hTR). In yet anotherembodiment of the present invention, the component of telomeraseincorporated in the compositions of the invention has an amino acidsequence with at least 90%, 95%, 98%, or 99% sequence homology to theamino acid sequence of a human telomerase reverse transcriptase (hTRT).In some embodiments of the invention, the components of telomerase areproduced via recombinant technology. These components of telomeraseenzyme may be obtained upon purification by known methods fromcommercial cell lines transfected with cDNA expressing the component,for example, e.g., hTRT. One example of such a cDNA is available fromCAMBIA.

Inhibitor of Telomerase.

In another embodiment of the invention, inhibition of inappropriatetelomerase activity by an inhibitor of a component of telomerase mayprovide utility for inclusion as a skin active. In some embodiments ofthe invention, the inhibitor to a component of a telomerase is a smallmolecule, a peptide, a nucleic acid, an oligonucleotide, or a protein.In some embodiments of the invention, the inhibitor is an antibody to acomponent of telomerase. In some embodiments of the invention, theantibody has an amino acid sequence with at least 90%, 95%, 98%, or 99%sequence homology to the amino acid sequence of an antibody to animaltelomerase. In other embodiments of the invention, the antibody has anamino acid sequence with at least 90%, 95%, 98%, or 99% sequencehomology to the amino acid sequence of an antibody to a component ofhuman telomerase. In some embodiments of the invention, the antibody isa human telomerase RT antibody. In some embodiments, the antibody is ahuman telomerase RNA antibody. An example of an antibody useful in skincare compositions is, for example, e.g., GTX30410 hTRT monoclonalantibody of human telomerase hTRT (clone 2C4), commercially availablefrom GeneTex, Inc. (San Antonio, Tex.), which is specific for human TRT.

Growth Factors.

Growth factors, which are proteins capable of stimulating cellularproliferation and cellular differentiation, may be included as skinactives in the compositions of the invention. Growth factors are dividedinto classes including Epidermal Growth Factor (EGF), TransformingGrowth Factor-β1 (TGF-β1), Vascular Endothelial Growth Factor (VEGF),Keratinocyte Growth Factors (KGF) and Fibroblast Growth Factor (FGF).Among the over twenty types of Fibroblast Growth Factors areKeratinocyte Growth Factors (KGF). These growth factors may be isolatedfrom animal sources or made be made using recombinant technology.

Epidermal Growth Factor (EGF) has been shown to promote proliferationand differentiation of mesenchymal and epithelial cells. In-vitro, EGFpromotes colony formation of epidermal cells in culture and in-vivo itpromotes epithelial development. In some embodiments the EGF has theamino acid sequence of the EGF of an animal. In other embodiments theEGF has the amino acid sequence of the EGF of a human. An example isrecombinant human EGF, commercially available form R&D Systems, which isan N-methionyl form of the 54 amino acid sequence of the natural maturehuman EGF, with a predicted molecular mass of about 6 kDa.

Transforming Growth Factor-β1 (TGF-β1) is one of a large and diversefamily of growth factors, i.e., including the bone morphogeneticproteins. TGF-β1 has multiple cell-context specific effects but may haveprotective effects on keratinocytes. In some embodiments, the TGF-β1 hasthe amino acid sequence of the TGF-β1 of an animal. In otherembodiments, the TGF-β1 has the sequence of the TGF-β1 of a human. Anexample of TGF-β1 is a disulfide linked homodimeric recombinant form ofhuman TGF-β1 (SEQ ID NO. 5), which is available from R&D Systems, with apredicted molecular mass of about 25 kDa.

Vascular Endothelial Growth Factor (VEGF) has the ability to increasepermeability of capillary vessels and promote angiogenesis. In someembodiments the VEGF has the amino acid sequence of the VEGF of ananimal. In other embodiments, the VEGF has the amino acid sequence ofthe VEGF of a human. An example is a disulfide linked homodimeric humanVEGF, which is available from R&D Systems and has a molecular mass ofabout 19-21 kDa.

The Fibroblast Growth Factor (FGF) family includes 22 known relatedcytokines which are involved in many functions including modulation ofcell proliferation, differentiation, and migration. FGFs bind attyrosine kinase receptors, and, in one aspect, are implicated in woundhealing in complicated, interrelated modes. FGFs 1, 2, 5, 7, and 10 areupregulated during healing. The use of one or more of the 22 memberedFGF family in the compositions of the invention may provide synergisticeffects in stimulating new epidermal growth, thus providing improvedskin conditioning.

The Keratinocyte Growth Factor subfamily of FGFs includes FGF-7 (alsoknown as KGF-1) and KGF-2 (also known as FGF-10). These two growthfactors are important in controlling epithelial cell behavior and cansignificantly promote re-epithelialization in both juvenile and matureanimals. In one embodiment of the invention, the Keratinocyte GrowthFactor is KGF-1. In another embodiment of the invention, theKeratinocyte Growth Factor is KGF-2. In another embodiment of theinvention, the Keratinocyte Growth Factor is KGF-1. In some embodimentsthe KGF has the amino acid sequence of the KGF of an animal. In otherembodiments, the KGF has the amino acid sequence of the KGF of a human.

In some embodiments of the invention, the composition contains anEpidermal Growth Factor and at least one Keratinocyte Growth Factor. Inother embodiments, the composition contains an Epidermal Growth Factor,at least one Keratinocyte Growth Factor, and Transforming GrowthFactor-β1. In yet other embodiments, the composition contains anEpidermal Growth Factor, at least one Keratinocyte Growth Factor,Transforming Growth Factor-β1, and a telomerase, which providessurprisingly efficacious use in topical treatment of skin. In yet otherembodiments, the composition contains an Epidermal Growth Factor, atleast one Keratinocyte Growth Factor, Transforming Growth Factor-β1, andan antibody to telomerase, which provides surprisingly efficacious usein topical treatment of skin.

Short Chain Peptides.

The use of short chain peptides, both with and without attached lipidmoieties, in skincare products, is known to those of skill in the art.For example, Olay Regenerist products, sold by Procter & Gamble,contain, Matrixyl®, a palmitoylated pentapeptide having the sequencePal-KTTKS. These additional skin care actives include peptidesincorporating about two to about eleven amino acids.

N-Modified Peptides.

Compositions of the present invention include at least one myristoylatedpeptide. As used in the present invention, by the term myristoylatedpeptide is meant a peptide having a sequence of from about two to abouteleven amino acids where a myristoyl group of the formula CH₃(CH₂)₁₂COO—is attached to the N-terminus of the amino acid sequence.

In one embodiment, the compositions of the present invention comprise atleast two acylated peptides having a sequence of from about two to abouteleven amino acids, where at least one of the acylated peptides ismyristoylated.

In another embodiment, the compositions of the present inventioncomprise at least two acylated peptides having a sequence of from abouttwo to about eleven amino acids, at least two of which aremyristoylated.

In yet another embodiment, the compositions of the present inventioncomprise at least two acylated peptides having a sequence of from abouttwo to about eleven amino acids, at least one of which is myristoylatedand one of which is palmitoylated. As used in the present invention, bythe term palmitoylated peptide is meant a peptide having a sequence offrom about two to about eleven amino acids where a palmitoyl group ofthe formula CH₃(CH₂)₁₄COO— is attached to the N-terminus of the aminoacid sequence.

Tri-, tetra-, penta-, hexa- and heptapeptides as well as oligopeptides(including palmitoyl and myristoyl derivatives thereof) suitable forincorporation in compositions of the present invention arecommercially-available from a number of suppliers and are described inthe International Cosmetic Ingredient Dictionary and Handbook (10^(th)Edition, 2003) published by the Cosmetics Toiletries and FragranceAssociation (“INCI Dictionary”). These include acylated peptides asdescribed in U.S. Pat. Nos. 6,974,799 and 6,492,326. These peptides maycomprise amino acid sequences which are homologous to portions of thesequences for Collagen 1.

In some embodiments of the invention, MYRISTOYL PENTAPEPTIDE-8 (MPP-GD),and MYRISTOYL PENTAPEPTIDE-11 (MPP-11), which are, for example,commercially available from Therapeutic Peptides, Inc. Harahan La., areincorporated in the skin care compositions. Another peptide, palmitoylpentapeptide-4, also known as MATRIXYL™, having the sequencepalmitoyl-Lys-Thr-Thr-Lys-Ser and commercially available fromPersonalformulator.com, Evanston, Wyo., may be incorporated in thecompositions of the invention.

B. Skin Benefit Ingredients

Compositions of the present invention may contain an antioxidant, ahumectant and/or a moisturizing agent. Other agents conferring a benefitmay also include antifungals, antibacterials, and anti-inflammatoryagents.

Antioxidants.

Antioxidants suitable for use in dermatological or cosmetic formulationsare well-known to those of skill in the art. Non-limiting examples ofantioxidants include the following: ascorbic acid and its salts,ascorbyl esters of fatty acids, ascorbic acid derivatives (e.g.,magnesium ascorbyl phosphate, sodium ascorbyl phosphate, ascorbylsorbate), tocopherol, tocopherol sorbate, tocopherol acetate, otheresters of tocopherol, butylated hydroxy benzoic acids and their salts,6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (commerciallyavailable under the tradename Trolox®), gallic acid and its alkyl esters(e.g., propyl gallate), nordihydroguaiaretic acid, bioflavonoids,quinones, and ubiquinones including Coenzyme Q and its derivatives.

Antioxidants are useful in the compositions of the invention to reducethe effects of oxidative stress, brighten skin tone, and reducehyperpigmentation, amongst their effects.

Ubiquinone.

Ubiquinone, also known as idebenone, is a quinone derivative. The use ofidebenone can be used in treating aging of the skin, wrinkling of theskin, ultraviolet radiation-induced damage, as well as oxidative and“degenerative” processes, by applying topical compositions having aneffective amount of idebenone or an idebenone derivative. Idenbenone oran idebenone derivative can be topically administered to reduce skinhyperpigmentation, skin irritation and/or inflammatory reactions in theskin. Idebenone may reduce the appearance of fine lines and wrinkles, aswell as skin roughness and dryness and to even skin tone.

Coenzyme Q is a ubiquinone having isoprenoid side chains and may beexpressed by the short-hand CoQ_(n), where n is the number of isoprenoidunits in the side chain. In one aspect of the present invention, n is aninteger ranging from 0 to 12, preferably from 1 to 12, and morepreferably from 6 to 10. In some embodiments, the Coenzyme Q, isCoenzyme Q₁₀.

Another aspect of the present invention relates to compositionscomprising ubiquinones not having an isoprenoid side chain. Theseinclude alkyl-ubiquinones in which the alkyl group contains from 1 to20, preferably from 1 to 12, carbon atoms. Non-limiting examples of suchubiquinones are decylubiquinones, 6-decylubiquinone, 2,3dimethoxy-5-decyl-1,4-ubiquinone, as well as derivatives and mixturesthereof.

Another antioxidant useful in the compositions of the invention arepolyphenolic bioflavonoids. In some embodiments of the invention, thecomposition comprises a green tea extract, which is an example of apolyphenolic bioflavonoid.

In some embodiments of the present invention, the composition comprisesCoenzyme Q or a derivative thereof. In other embodiments, thecomposition comprises a bioflavonoid. In yet other embodiments, thecomposition comprises a polyphenol.

Other Antioxidants.

Other compounds with an antioxidant effect useful in the compositions ofthe invention alpha hydroxy acids (AHAs), poly-AHAs, complex poly-AHAs,retinoids, fish polysaccharides, anti-enzymatic agents, antioxidantssuch as ascorbic acid, pycnogenol, ursolic acid, vegetable isoflavones,vitamins A, C, and E, lipoic acid, resveratrol, 1-carnosine and taurine,agaricic acid, various plant extracts, and their derivatives. In someembodiments of the invention, one or more antioxidants are chosen fromthe group comprising retinyl palmitate, magnesium ascorbyl phosphate,sodium ascorbyl phosphate and tocopherol acetate.

Humectants.

Humectants suitable for use in dermatological or cosmetic formulationsto assist in moisturizing skin are well-known to those of skill in theart and are taught in U.S. Pat. No. 6,492,326. Preferred, butnon-limiting, examples of humectants and moisturizing agents include:sodium hyaluronate, D,L-panthenol, D-panthenol, methylsilanolmannuronate, natural oils (e.g., borage oil, evening primrose oil),C₆-C₂₂ fatty acid esters of glycerol, butylene glycol, silicones andsilicone derivatives.

Other Anti-Inflammatory Agents.

Other anti-inflammatory agents which may be incorporated into thecompositions of the invention include, but are not limited to mefenamicacid or derivatives thereof; phenylbutazone or derivatives thereof;indomethacin or derivatives thereof; ibuprofen or derivatives thereof;ketoprofen or derivatives thereof; ε-aminocapronic acid; sodiumdiclofenac; diphenhydramine; tranexamic acid or derivatives thereof;dexamethasone; cortisone or esters thereof; hydrocortisone or estersthereof; adrenal cortical hormone such as prednisone and prednisolone;and antihistamic agent.

Anti-Fungal and Anti-Microbial Agents.

Antimicrobial and antifungal agents may be incorporated into thecompositions of the invention include but are not limited to beta-lactamdrugs, quinolone drugs, ciprofloxacin, norfloxacin, tetracycline,erythromycin, amikacin, 2,4,4′-trichloro-2′-hydroxy diphenyl ether,3,4,4′-trichlorobanilide, phenoxyethanol, phenoxy propanol,phenoxyisopropanol, doxycycline, capreomycin, chlorhexidine,chlortetracycline, oxytetracycline, clindamycin, ethambutol, hexamidineisethionate, metronidazole, pentamidine, gentamicin, kanamycin,lineomycin, methacycline, methenamine, minocycline, neomycin,netilmicin, paromomycin, streptomycin, tobramycin, miconazole,tetracycline hydrochloride, erythromycin, zinc erythromycin,erythromycin estolate, erythromycin stearate, amikacin sulfate,doxycycline hydrochloride, capreomycin sulfate, chlorhexidine gluconate,chlorhexidine hydrochloride, chlortetracycline hydrochloride,oxytetracycline hydrochloride, clindamycin hydrochloride, ethambutolhydrochloride, metronidazole hydrochloride, pentamidine hydrochloride,gentamicin sulfate, kanamycin sulfate, lineomycin hydrochloride,methacycline hydrochloride, methenamine hippurate, methenaminemandelate, minocycline hydrochloride, neomycin sulfate, netilmicinsulfate, paromomycin sulfate, streptomycin sulfate, tobramycin sulfate,miconazole hydrochloride, amanfadine hydrochloride, amanfadine sulfate,octopirox, parachlorometa xylenol, nystatin, tolnaftate andclotrimazole.

II. Formulations

In some embodiments, Telomerase RNA is present in compositions of thepresent invention at concentrations of at least from about 0.000001% w/wto about 0.01% w/w; at least from about 0.000005% w/w to about 0.005%w/w; at least from about 0.00001% w/w to about 0.001% w/w; at least fromabout 0.00005% w/w to about 0.001% w/w, or at least from about 0.0001%w/w to about 0.001% w/w. In some embodiments, Telomerase RNA is presentin compositions of the present invention at concentrations of more thanabout 0.000001%; 0.000002%; 0.000003%; 0.000004%; 0.000005%; 0.000006%;0.000007%; 0.000008%; 0.000009%; 0.00001%; 0.00002%; 0.00003%; 0.00004%;0.00005%; 0.00006%; 0.00007%; 0.00008%; 0.00009%; 0.0001%; 0.0002%;0.0003%; 0.0004%; 0.0005%; 0.0006%; 0.0007%; 0.0008%; 0.0009%; 0.001%;0.002%; 0.003%; 0.004%; 0.005%; 0.006%; 0.007%; 0.008%; 0.009%, or 0.01%w/w. In some embodiments, Telomerase RNA is present in compositions ofthe present invention at concentrations of less than about 0.01%;0.009%; 0.008%; 0.007%; 0.006%; 0.005%; 0.004%; 0.003%; 0.002%; 0.001%;0.0009%; 0.0008%; 0.0007%; 0.0006%; 0.0005%; 0.0004%; 0.0003%; 0.0002%;0.0001%; 0.00009%; 0.00008%; 0.00007%; 0.00006%; 0.00005%; 0.00004%;0.00003%; 0.00002%; 0.00001%; 0.000009%; 0.000008%; 0.000007%;0.000006%; 0.000005%; 0.000004%; 0.000003%; 0.000002%; or 0.000001% w/w.

In some embodiments, Telomerase RT is present in compositions of thepresent invention at concentrations of at least from about 0.000001% w/wto about 0.01% w/w; at least from about 0.000005% w/w to about 0.005%w/w; at least from about 0.00001% w/w to about 0.001% w/w; at least fromabout 0.00005% w/w to about 0.001% w/w, or at least from about 0.0001%w/w to about 0.001% w/w. In some embodiments, Telomerase RT is presentin compositions of the present invention at concentrations of more thanabout 0.000001%; 0.000002%; 0.000003%; 0.000004%; 0.000005%; 0.000006%;0.000007%; 0.000008%; 0.000009%; 0.00001%; 0.00002%; 0.00003%; 0.00004%;0.00005%; 0.00006%; 0.00007%; 0.00008%; 0.00009%; 0.0001%; 0.0002%;0.0003%; 0.0004%; 0.0005%; 0.0006%; 0.0007%; 0.0008%; 0.0009%; 0.001%;0.002%; 0.003%; 0.004%; 0.005%; 0.006%; 0.007%; 0.008%; 0.009%, or 0.01%w/w. In some embodiments, Telomerase RT is present in compositions ofthe present invention at concentrations of less than about 0.01%;0.009%; 0.008%; 0.007%; 0.006%; 0.005%; 0.004%; 0.003%; 0.002%; 0.001%;0.0009%; 0.0008%; 0.0007%; 0.0006%; 0.0005%; 0.0004%; 0.0003%; 0.0002%;0.0001%; 0.00009%; 0.00008%; 0.00007%; 0.00006%; 0.00005%; 0.00004%;0.00003%; 0.00002%; 0.00001%; 0.000009%; 0.000008%; 0.000007%;0.000006%; 0.000005%; 0.000004%; 0.000003%; 0.000002%; or 0.000001% w/w.

In some embodiments, antibody to Telomerase RT is present incompositions of the present invention at concentrations of at least fromabout 0.000001% w/w to about 0.01% w/w; at least from about 0.000005%w/w to about 0.005% w/w; at least from about 0.00001% w/w to about0.001% w/w; at least from about 0.00005% w/w to about 0.001% w/w, or atleast from about 0.0001% w/w to about 0.001% w/w. In some embodiments,antibody to Telomerase RT is present in compositions of the presentinvention at concentrations of more than about 0.000001%; 0.000002%;0.000003%; 0.000004%; 0.000005%; 0.000006%; 0.000007%; 0.000008%;0.000009%; 0.00001%; 0.00002%; 0.00003%; 0.00004%; 0.00005%; 0.00006%;0.00007%; 0.00008%; 0.00009%; 0.0001%; 0.0002%; 0.0003%; 0.0004%;0.0005%; 0.0006%; 0.0007%; 0.0008%; 0.0009%; 0.001%; 0.002%; 0.003%;0.004%; 0.005%; 0.006%; 0.007%; 0.008%; 0.009%, or 0.01% w/w. In someembodiments, antibody to Telomerase RT is present in compositions of thepresent invention at concentrations of less than about 0.01%; 0.009%;0.008%; 0.007%; 0.006%; 0.005%; 0.004%; 0.003%; 0.002%; 0.001%; 0.0009%;0.0008%; 0.0007%; 0.0006%; 0.0005%; 0.0004%; 0.0003%; 0.0002%; 0.0001%;0.00009%; 0.00008%; 0.00007%; 0.00006%; 0.00005%; 0.00004%; 0.00003%;0.00002%; 0.00001%; 0.000009%; 0.000008%; 0.000007%; 0.000006%;0.000005%; 0.000004%; 0.000003%; 0.000002%; or 0.000001% w/w.

In some embodiments, EGF is present in compositions of the presentinvention at concentrations of at least from about 0.000001% w/w toabout 0.001% w/w; at least from about 0.000001% w/w to about 0.0005%w/w; at least from about 0.000001% w/w to about 0.0001% w/w; or at leastfrom about 0.00001% w/w to about 0.005% w/w. In some embodiments, EGF ispresent in compositions of the present invention at concentrations of atleast about 0.000001%; 0.0000015%; 0.000002%; 0.0000025%; 0.000003%;0.0000035%; 0.000004%; 0.0000045%; 0.000005%; 0.0000055%; 0.000006%;0.0000065%; 0.000007%; 0.0000075%; 0.000008%; 0.0000085%; 0.000009%;0.0000095%; 0.00001%; 0.000015%; 0.00002%; 0.000025%; 0.00003%;0.000035%; 0.00004%; 0.000045%; 0.00005%; 0.000055%; 0.00006%;0.000065%; 0.00007%; 0.000075%; 0.00008%; 0.000085%; 0.00009%;0.000095%; 0.0001%; 0.00015%; 0.0002%; 0.00025%; 0.0003%; 0.00035%;0.0004%; 0.00045%; 0.0005%; 0.00055% 0.0006%; 0.00065%; 0.0007%;0.00075%; 0.0008%; 0.00085%; 0.0009%; 0.00095%; or 0.001% w/w. In someembodiments, EGF is present in compositions of the present invention atconcentrations of less than about 0.001%; 0.00095%; 0.0009%; 0.00085%;0.0008%; 0.00075%; 0.0007%; 0.00065%; 0.0006%; 0.00055%; 0.0005%;0.00045%; 0.0004%; 0.00035%; 0.0003%; 0.00025%; 0.0002%; 0.00015%;0.000095%; 0.00009%; 0.000085%; 0.00008%; 0.000075%; 0.00007%;0.000065%; 0.00006%; 0.000055%; 0.00005%; 0.000045%; 0.00004%;0.000035%; 0.00003%; 0.000025%; 0.00002%; 0.000015%; or 0.00001% w/w.

In some embodiments, VEGF is present in compositions of the presentinvention at concentrations of at least from about 0.000001% w/w toabout 0.001% w/w; at least from about 0.000001% w/w to about 0.0005%w/w; at least from about 0.000001% w/w to about 0.0001% w/w; or at leastfrom about 0.000001% w/w to about 0.005% w/w. In some embodiments, VEGFis present in compositions of the present invention at concentrations ofat least about 0.000001%; 0.0000015%; 0.000002%; 0.0000025%; 0.000003%;0.0000035%; 0.000004%; 0.0000045%; 0.000005%; 0.0000055%; 0.000006%;0.0000065%; 0.000007%; 0.0000075%; 0.000008%; 0.0000085%; 0.000009%;0.0000095%; 0.00001%; 0.000015%; 0.00002%; 0.000025%; 0.00003%;0.000035%; 0.00004%; 0.000045%; 0.00005%; 0.000055%; 0.00006%;0.000065%; 0.00007%; 0.000075%; 0.00008%; 0.000085%; 0.00009%;0.000095%; 0.0001%; 0.00015%; 0.0002%; 0.00025%; 0.0003%; 0.00035%;0.0004%; 0.00045%; 0.0005%; 0.00055% 0.0006%; 0.00065%; 0.0007%;0.00075%; 0.0008%; 0.00085%; 0.0009%; 0.00095%; or 0.001% w/w. In someembodiments, VEGF is present in compositions of the present invention atconcentrations of less than about 0.001%; 0.00095%; 0.0009%; 0.00085%;0.0008%; 0.00075%; 0.0007%; 0.00065%; 0.0006%; 0.00055%; 0.0005%;0.00045%; 0.0004%; 0.00035%; 0.0003%; 0.00025%; 0.0002%; 0.00015%;0.000095%; 0.00009%; 0.000085%; 0.00008%; 0.000075%; 0.00007%;0.000065%; 0.00006%; 0.000055%; 0.00005%; 0.000045%; 0.00004%;0.000035%; 0.00003%; 0.000025%; 0.00002%; 0.000015%; 0.00001%;0.000009%; 0.000008%; 0.000007%; 0.000006%; 0.000005%; 0.000004%;0.000003%; 0.000002%; or 0.000001% w/w.

In some embodiments, a FGF is present in the compositions of the presentinvention at concentrations of at least from about 0.000001% w/w toabout 0.01% w/w; at least from about 0.000001% w/w to about 0.001% w/w;or at least from about 0.000001% w/w to about 0.0001% w/w. In someembodiments, a FGF is present in the compositions of the presentinvention at concentrations of at least about 0.000001%; 0.0000015%;0.000002%; 0.0000025%; 0.000003%; 0.0000035%; 0.000004%; 0.0000045%;0.000005%; 0.0000055%; 0.000006%; 0.0000065%; 0.000007%; 0.0000075%;0.000008%; 0.0000085%; 0.000009%; 0.0000095%; 0.00001%; 0.000015%;0.00002%; 0.000025%; 0.00003%; 0.000035%; 0.00004%; 0.000045%; 0.00005%;0.000055%; 0.00006%; 0.000065%; 0.00007%; 0.000075%; 0.00008%;0.000085%; 0.00009%; 0.000095%; 0.0001%; 0.00015%; 0.0002%; 0.00025%;0.0003%; 0.00035%; 0.0004%; 0.00045%; 0.0005%; 0.00055% 0.0006%;0.00065%; 0.0007%; 0.00075%; 0.0008%; 0.00085%; 0.0009%; 0.00095%; or0.001% w/w. In some embodiments, a FGF is present in the compositions atconcentrations less than about 0.01%; 0.009%; 0.008%; 0.007%; 0.006%;0.005%; 0.004%; 0.003%; 0.002%; 0.001%; 0.00095%; 0.0009%; 0.00085%;0.0008%; 0.00075%; 0.0007%; 0.00065%; 0.0006%; 0.00055%; 0.0005%;0.00045%; 0.0004%; 0.00035%; 0.0003%; 0.00025%; 0.0002%; 0.00015%;0.000095%; 0.00009%; 0.000085%; 0.00008%; 0.000075%; 0.00007%;0.000065%; 0.00006%; 0.000055%; 0.00005%; 0.000045%; 0.00004%;0.000035%; 0.00003%; 0.000025%; 0.00002%; 0.000015%; 0.00001%;0.000009%; 0.000008%; 0.000007%; 0.000006%; 0.000005%; 0.000004%;0.000003%; 0.000002%; or 0.000001% w/w. In some embodiments, more thanone FGF is present in the compositions of the present invention, eachindependently at concentrations of at least from about 0.000001% w/w toabout 0.01% w/w; at least from about 0.000001% w/w to about 0.001% w/w;or at least from about 0.000001% w/w to about 0.0001% w/w. More than oneFGF may be present in the compositions of the present invention, eachindependently at concentrations of at least about 0.000001%; 0.0000015%;0.000002%; 0.0000025%; 0.000003%; 0.0000035%; 0.000004%; 0.0000045%;0.000005%; 0.0000055%; 0.000006%; 0.0000065%; 0.000007%; 0.0000075%;0.000008%; 0.0000085%; 0.000009%; 0.0000095%; 0.00001%; 0.000015%;0.00002%; 0.000025%; 0.00003%; 0.000035%; 0.00004%; 0.000045%; 0.00005%;0.000055%; 0.00006%; 0.000065%; 0.00007%; 0.000075%; 0.00008%;0.000085%; 0.00009%; 0.000095%; 0.0001%; 0.00015%; 0.0002%; 0.00025%;0.0003%; 0.00035%; 0.0004%; 0.00045%; 0.0005%; 0.00055% 0.0006%;0.00065%; 0.0007%; 0.00075%; 0.0008%; 0.00085%; 0.0009%; 0.00095%; or0.001% w/w. In some embodiments, more than one FGF is present in thecompositions, each independently at concentrations less than about0.01%; 0.009%; 0.008%; 0.007%; 0.006%; 0.005%; 0.004%; 0.003%; 0.002%;0.001%; 0.00095%; 0.0009%; 0.00085%; 0.0008%; 0.00075%; 0.0007%;0.00065%; 0.0006%; 0.00055%; 0.0005%; 0.00045%; 0.0004%; 0.00035%;0.0003%; 0.00025%; 0.0002%; 0.00015%; 0.000095%; 0.00009%; 0.000085%;0.00008%; 0.000075%; 0.00007%; 0.000065%; 0.00006%; 0.000055%; 0.00005%;0.000045%; 0.00004%; 0.000035%; 0.00003%; 0.000025%; 0.00002%;0.000015%; 0.00001%; 0.000009%; 0.000008%; 0.000007%; 0.000006%;0.000005%; 0.000004%; 0.000003%; 0.000002%; or 0.000001% w/w.

In some embodiments, KGF-1 is present in the compositions of the presentinvention at concentrations of at least from about 0.000001% w/w toabout 0.01% w/w; at least from about 0.000001% w/w to about 0.001% w/w;or at least from about 0.000001% w/w to about 0.0001% w/w. In someembodiments, KGF-1 is present in the compositions of the presentinvention at concentrations of at least about 0.000001%; 0.0000015%;0.000002%; 0.0000025%; 0.000003%; 0.0000035%; 0.000004%; 0.0000045%;0.000005%; 0.0000055%; 0.000006%; 0.0000065%; 0.000007%; 0.0000075%;0.000008%; 0.0000085%; 0.000009%; 0.0000095%; 0.00001%; 0.000015%;0.00002%; 0.000025%; 0.00003%; 0.000035%; 0.00004%; 0.000045%; 0.00005%;0.000055%; 0.00006%; 0.000065%; 0.00007%; 0.000075%; 0.00008%;0.000085%; 0.00009%; 0.000095%; 0.0001%; 0.00015%; 0.0002%; 0.00025%;0.0003%; 0.00035%; 0.0004%; 0.00045%; 0.0005%; 0.00055% 0.0006%;0.00065%; 0.0007%; 0.00075%; 0.0008%; 0.00085%; 0.0009%; 0.00095%; or0.001% w/w. In other embodiments, KGF-1 is present in the compositionsat concentrations less than about 0.01%; 0.009%; 0.008%; 0.007%; 0.006%;0.005%; 0.004%; 0.003%; 0.002%; 0.001%; 0.00095%; 0.0009%; 0.00085%;0.0008%; 0.00075%; 0.0007%; 0.00065%; 0.0006%; 0.00055%; 0.0005%;0.00045%; 0.0004%; 0.00035%; 0.0003%; 0.00025%; 0.0002%; 0.00015%;0.000095%; 0.00009%; 0.000085%; 0.00008%; 0.000075%; 0.00007%;0.000065%; 0.00006%; 0.000055%; 0.00005%; 0.000045%; 0.00004%;0.000035%; 0.00003%; 0.000025%; 0.00002%; 0.000015%; 0.00001%;0.000009%; 0.000008%; 0.000007%; 0.000006%; 0.000005%; 0.000004%;0.000003%; 0.000002%; or 0.000001% w/w.

In some embodiments, KGF-2 is present in the compositions of the presentinvention at concentrations of at least from about 0.000001% w/w toabout 0.01% w/w; at least from about 0.000001% w/w to about 0.001% w/w;or at least from about 0.000001% w/w to about 0.0001% w/w. In otherembodiments, KGF-2 is present in the compositions of the presentinvention at concentrations of at least about 0.000001%; 0.0000015%;0.000002%; 0.0000025%; 0.000003%; 0.0000035%; 0.000004%; 0.0000045%;0.000005%; 0.0000055%; 0.000006%; 0.0000065%; 0.000007%; 0.0000075%;0.000008%; 0.0000085%; 0.000009%; 0.0000095%; 0.00001%; 0.000015%;0.00002%; 0.000025%; 0.00003%; 0.000035%; 0.00004%; 0.000045%; 0.00005%;0.000055%; 0.00006%; 0.000065%; 0.00007%; 0.000075%; 0.00008%;0.000085%; 0.00009%; 0.000095%; 0.0001%; 0.00015%; 0.0002%; 0.00025%;0.0003%; 0.00035%; 0.0004%; 0.00045%; 0.0005%; 0.00055% 0.0006%;0.00065%; 0.0007%; 0.00075%; 0.0008%; 0.00085%; 0.0009%; 0.00095%; or0.001% w/w. In yet other embodiments, KGF-2 is present in thecompositions at concentrations less than about 0.01%; 0.009%; 0.008%;0.007%; 0.006%; 0.005%; 0.004%; 0.003%; 0.002%; 0.001%; 0.00095%;0.0009%; 0.00085%; 0.0008%; 0.00075%; 0.0007%; 0.00065%; 0.0006%;0.00055%; 0.0005%; 0.00045%; 0.0004%; 0.00035%; 0.0003%; 0.00025%;0.0002%; 0.00015%; 0.000095%; 0.00009%; 0.000085%; 0.00008%; 0.000075%;0.00007%; 0.000065%; 0.00006%; 0.000055%; 0.00005%; 0.000045%; 0.00004%;0.000035%; 0.00003%; 0.000025%; 0.00002%; 0.000015%; 0.00001%;0.000009%; 0.000008%; 0.000007%; 0.000006%; 0.000005%; 0.000004%;0.000003%; 0.000002%; or 0.000001% w/w.

In some embodiments, Transforming Growth Factor-β1 is present incompositions of the present invention at concentrations of at least fromabout 0.000001% w/w to about 0.001% w/w; at least from about 0.000001%w/w to about 0.0005% w/w; at least from about 0.000001% w/w to about0.0001% w/w; or at least from about 0.000001% w/w to about 0.0001% w/w.In some embodiments, Transforming Growth Factor-β1 is present incompositions of the present invention at concentrations of at leastabout 0.000001%; 0.0000015%; 0.000002%; 0.0000025%; 0.000003%;0.0000035%; 0.000004%; 0.0000045%; 0.000005%; 0.0000055%; 0.000006%;0.0000065%; 0.000007%; 0.0000075%; 0.000008%; 0.0000085%; 0.000009%;0.0000095%; 0.00001%; 0.000015%; 0.00002%; 0.000025%; 0.00003%;0.000035%; 0.00004%; 0.000045%; 0.00005%; 0.000055%; 0.00006%;0.000065%; 0.00007%; 0.000075%; 0.00008%; 0.000085%; 0.00009%;0.000095%; 0.0001%; 0.00015%; 0.0002%; 0.00025%; 0.0003%; 0.00035%;0.0004%; 0.00045%; 0.0005%; 0.00055% 0.0006%; 0.00065%; 0.0007%;0.00075%; 0.0008%; 0.00085%; 0.0009%; 0.00095%; or 0.001% w/w. In someembodiments, Transforming Growth Factor-β1 is present in compositions ofthe present invention at concentrations of less than about 0.001%;0.00095%; 0.0009%; 0.00085%; 0.0008%; 0.00075%; 0.0007%; 0.00065%;0.0006%; 0.00055%; 0.0005%; 0.00045%; 0.0004%; 0.00035%; 0.0003%;0.00025%; 0.0002%; 0.00015%; 0.000095%; 0.00009%; 0.000085%; 0.00008%;0.000075%; 0.00007%; 0.000065%; 0.00006%; 0.000055%; 0.00005%;0.000045%; 0.00004%; 0.000035%; 0.00003%; 0.000025%; 0.00002%;0.000015%; or 0.00001% w/w.

In some embodiments, a myristoylated peptide is present in thecompositions of the invention at concentrations of at least from about0.001% w/w to about 2.0% w/w; at least from about 0.01% w/w to about2.0% w/w; at least from about 0.05% w/w to about 2.0% w/w or at leastfrom about 0.01% w/w to about 2.0% w/w. In some embodiments, amyristoylated peptide is present in the compositions of the invention atconcentrations of at least about 0.001%; 0.002%; 0.003%; 0.004%; 0.005%;0.006%; 0.007%; 0.008%; 0.009%; 0.01%; 0.02%; 0.03%; 0.04%; 0.05%;0.06%; 0.07%; 0.08%; 0.09%; 0.10%; 0.15%; 0.20%; 0.25%; 0.30%; 0.35%;0.40%; 0.45%; 0.50%; 0.55%; 0.60%; 0.65%; 0.70%; 0.75%; 0.80%; 0.85%;0.90%; 0.95%; 1.00%; 1.10%; 1.20%; 1.30%; 1.40%; 1.45%; 1.50%; 1.60%;1.70%; 1.80%; 1.90% or 2.00% w/w. In some embodiments, a myristoylatedpeptide is present in the compositions of the invention atconcentrations less than about 2.00%; 1.90%; 1.80%; 1.70%; 1.60%; 1.50%;1.40%; 1.370%; 1.20%; 1.10%; 1.00%; 0.90%; 0.85%; 0.80%; 0.75%; 0.70%;0.65%; 0.60%; 0.55%; 0.50%; 0.45%; 0.40%; 0.35%; 0.30%; 0.25%; 0.20%;0.15%; 0.10%; 0.05%; 0.001%, 0.009%; 0.008%; 0.007%; 0.006%; 0.005%;0.004%; 0.003%; 0.002%; or 0.0001% w/w. In some embodiments, more thanone myristoylated peptide is present in the compositions of theinventions, each independently at concentrations of at least from about0.001% w/w to about 2.0% w/w; at least from about 0.01% w/w to about2.0% w/w; at least from about 0.05% w/w to about 2.0% w/w or at leastfrom about 0.01% w/w to about 2.0% w/w. In some embodiments, more thanone myristoylated peptide is present in the compositions of theinvention, each independently at concentrations of at least about0.001%; 0.002%; 0.003%; 0.004%; 0.005%; 0.006%; 0.007%; 0.008%; 0.009%;0.01%; 0.02%; 0.03%; 0.04%; 0.05%; 0.06%; 0.07%; 0.08%; 0.09%; 0.10%;0.15%; 0.20%; 0.25%; 0.30%; 0.35%; 0.40%; 0.45%; 0.50%; 0.55%; 0.60%;0.65%; 0.70%; 0.75%; 0.80%; 0.85%; 0.90%; 0.95%; 1.00%; 1.10%; 1.20%;1.30%; 1.40%; 1.45%; 1.50%; 1.60%; 1.70%; 1.80%; 1.90% or 2.00% w/w. Insome embodiments, more than one myristoylated peptide is present in thecompositions of the invention, each independently at concentrations lessthan about 2.00%; 1.90%; 1.80%; 1.70%; 1.60%; 1.50%; 1.40%; 1.370%;1.20%; 1.10%; 1.00%; 0.90%; 0.85%; 0.80%; 0.75%; 0.70%; 0.65%; 0.60%;0.55%; 0.50%; 0.45%; 0.40%; 0.35%; 0.30%; 0.25%; 0.20%; 0.15%; 0.10%;0.05%; 0.001%; 0.009%; 0.008%; 0.007%; 0.006%; 0.005%; 0.004%; 0.003%;0.002%; or 0.0001% w/w.

A palmitoylated peptide may be present in the compositions of thepresent invention at concentrations of at least from about 0.50% w/w toabout 6.00% w/w. In some embodiments, a palmitoylated peptide is presentin the compositions of the invention at concentrations of at least about0.50%; 0.60%; 0.70%; 0.80%; 0.90%; 1.10%; 1.20%; 1.30%; 1.40%; 1.50%;1.60%; 1.70%; 1.80%; 1.90%; 2.00%; 2.10%; 2.20%; 2.30%; 2.40%; 2.50%;2.60%; 2.70%; 2.80%; 2.90%; 3.00%; 3.10%; 3.20%; 3.30%; 3.40%; 3.50%;3.60%; 3.70%; 3.80%; 3.90%; 4.00%; 4.10%; 4.20%; 4.30%; 4.40%; 4.50%;4.60%; 4.70%; 4.80%; 4.90%; 5.00%; 5.10%; 5.20%; 5.30%; 5.40%; 5.50%;5.60%; 5.70%; 5.80%; 5.90% or 6.00% w/w. In some embodiments, apalmitoylated peptide is present in the compositions of the invention atconcentrations of less than about 6.00%; 5.90%; 5.80%; 5.70%; 5.60%;5.50%; 5.40%; 5.30%; 5.20%; 5.10%; 5.00%; 4.90%; 4.80%; 4.70%; 4.60%;4.50%; 4.40%; 4.30%; 4.20%; 4.10%; 4.00%; 3.90%; 3.80%; 3.70%; 3.60%;3.50%; 3.40%; 3.30%; 3.20%; 3.10%; 3.00%; 2.90%; 2.90%; 2.80%; 2.70%;2.60%; 2.50%; 240%; 2.30%; 2.20%; 2.10%; 2.00%; 1.90%; 1.80%; 1.70%;1.60%; 1.50%; 1.40%; 1.30%; 1.20%; 1.10%; 1.00%; 0.90%; 0.80%; 0.70%;0.60%; or 0.50% w/w. In some embodiments, more than one palmitoylatedpeptide is present in the compositions of the invention eachindependently at concentrations of at least about 0.50%; 0.60%; 0.70%;0.80%; 0.90%; 1.10%; 1.20%; 1.30%; 1.40%; 1.50%; 1.60%; 1.70%; 1.80%;1.90%; 2.00%; 2.10%; 2.20%; 2.30%; 2.40%; 2.50%; 2.60%; 2.70%; 2.80%;2.90%; 3.00%; 3.10%; 3.20%; 3.30%; 3.40%; 3.50%; 3.60%; 3.70%; 3.80%;3.90%; 4.00%; 4.10%; 4.20%; 4.30%; 4.40%; 4.50%; 4.60%; 4.70%; 4.80%;4.90%; 5.00%; 5.10%; 5.20%; 5.30%; 5.40%; 5.50%; 5.60%; 5.70%; 5.80%;5.90% or 6.00% w/w. In some embodiments, more than one palmitoylatedpeptide is present in the compositions of the invention, eachindependently at concentrations of less than about 6.00%; 5.90%; 5.80%;5.70%; 5.60%; 5.50%; 5.40%; 5.30%; 5.20%; 5.10%; 5.00%; 4.90%; 4.80%;4.70%; 4.60%; 4.50%; 4.40%; 4.30%; 4.20%; 4.10%; 4.00%; 3.90%; 3.80%;3.70%; 3.60%; 3.50%; 3.40%; 3.30%; 3.20%; 3.10%; 3.00%; 2.90%; 2.90%;2.80%; 2.70%; 2.60%; 2.50%; 240%; 2.30%; 2.20%; 2.10%; 2.00%; 1.90%;1.80%; 1.70%; 1.60%; 1.50%; 1.40%; 1.30%; 1.20%; 1.10%; 1.00%; 0.90%;0.80%; 0.70%; 0.60%; or 0.50% w/w.

In some embodiments, one or more antioxidants are present in thecompositions of the invention, each independently at concentrationspresent in the compositions of the invention at concentrations of atleast from about 0.001% w/w to about 2.0% w/w; at least from about 0.01%w/w to about 2.0% w/w; at least from about 0.05% w/w to about 2.0% w/wor at least from about 0.01% w/w to about 2.0% w/w. In some embodiments,one or more antioxidants are present in the compositions of theinvention, each independently at concentrations of at least about0.001%; 0.002%; 0.003%; 0.004%; 0.005%; 0.006%; 0.007%; 0.008%; 0.009%;0.01%; 0.02%; 0.03%; 0.04%; 0.05%; 0.06%; 0.07%; 0.08%; 0.09%; 0.10%;0.15%; 0.20%; 0.25%; 0.30%; 0.35%; 0.40%; 0.45%; 0.50%; 0.55%; 0.60%;0.65%; 0.70%; 0.75%; 0.80%; 0.85%; 0.90%; 0.95%; 1.00%; 1.10%; 1.20%;1.30%; 1.40%; 1.45%; 1.50%; 1.60%; 1.70%; 1.80%; 1.90%; or 2.00% w/w. Insome embodiments, one or more antioxidants are present in thecompositions of the invention, each independently at concentrations lessthan about 2.00%; 1.90%; 1.80%; 1.70%; 1.60%; 1.50%; 1.40%; 1.370%;1.20%; 1.10%; 1.00%; 0.90%; 0.85%; 0.80%; 0.75%; 0.70%; 0.65%; 0.60%;0.55%; 0.50%; 0.45%; 0.40%; 0.35%; 0.30%; 0.25%; 0.20%; 0.15%; 0.10%;0.05%; 0.001%; 0.009%; 0.008%; 0.007%; 0.006%; 0.005%; 0.004%; 0.003%;0.002%; or 0.0001% w/w.

In some embodiments, ubiquinone is present in the compositions of theinvention at concentrations present in the compositions of the inventionat concentrations of at least from about 0.001% w/w to about 2.0% w/w;at least from about 0.01% w/w to about 2.0% w/w; at least from about0.05% w/w to about 2.0% w/w or at least from about 0.01% w/w to about2.0% w/w. In some embodiments, ubiquinone is present in the compositionsof the invention, at concentrations of at least about 0.001%; 0.002%;0.003%; 0.004%; 0.005%; 0.006%; 0.007%; 0.008%; 0.009%; 0.01%; 0.02%;0.03%; 0.04%; 0.05%; 0.06%; 0.07%; 0.08%; 0.09%; 0.10%; 0.15%; 0.20%;0.25%; 0.30%; 0.35%; 0.40%; 0.45%; 0.50%; 0.55%; 0.60%; 0.65%; 0.70%;0.75%; 0.80%; 0.85%; 0.90%; 0.95%; 1.00%; 1.10%; 1.20%; 1.30%; 1.40%;1.45%; 1.50%; 1.60%; 1.70%; 1.80%; 1.90%; or 2.00% w/w. In someembodiments, ubiquinone is present in the compositions of the inventionat concentrations less than about 2.00%; 1.90%; 1.80%; 1.70%; 1.60%;1.50%; 1.40%; 1.370%; 1.20%; 1.10%; 1.00%; 0.90%; 0.85%; 0.80%; 0.75%;0.70%; 0.65%; 0.60%; 0.55%; 0.50%; 0.45%; 0.40%; 0.35%; 0.30%; 0.25%;0.20%; 0.15%; 0.10%; 0.05%; 0.001%; 0.009%; 0.008%; 0.007%; 0.006%;0.005%; 0.004%; 0.003%; 0.002%; or 0.0001% w/w.

In some embodiments, green tea extract is present in the compositions ofthe invention at concentrations present in the compositions of theinvention at concentrations of at least from about 0.001% w/w to about2.0% w/w; at least from about 0.01% w/w to about 2.0% w/w; at least fromabout 0.05% w/w to about 2.0% w/w or at least from about 0.01% w/w toabout 2.0% w/w. In some embodiments, green tea extract is present in thecompositions of the invention, at concentrations of at least about0.001%; 0.002%; 0.003%; 0.004%; 0.005%; 0.006%; 0.007%; 0.008%; 0.009%;0.01%; 0.02%; 0.03%; 0.04%; 0.05%; 0.06%; 0.07%; 0.08%; 0.09%; 0.10%;0.15%; 0.20%; 0.25%; 0.30%; 0.35%; 0.40%; 0.45%; 0.50%; 0.55%; 0.60%;0.65%; 0.70%; 0.75%; 0.80%; 0.85%; 0.90%; 0.95%; 1.00%; 1.10%; 1.20%;1.30%; 1.40%; 1.45%; 1.50%; 1.60%; 1.70%; 1.80%; 1.90%; or 2.00% w/w. Insome embodiments, green tea extract is present in the compositions ofthe invention at concentrations less than about 2.00%; 1.90%; 1.80%;1.70%; 1.60%; 1.50%; 1.40%; 1.370%; 1.20%; 1.10%; 1.00%; 0.90%; 0.85%;0.80%; 0.75%; 0.70%; 0.65%; 0.60%; 0.55%; 0.50%; 0.45%; 0.40%; 0.35%;0.30%; 0.25%; 0.20%; 0.15%; 0.10%; 0.05%; 0.001%; 0.009%; 0.008%;0.007%; 0.006%; 0.005%; 0.004%; 0.003%; 0.002%; or 0.0001% w/w.

The compositions of the present invention may contain a wide range ofadditional components. These include emollients, film forming agents,emulsifiers, thickening agents and other rheological modifiers.Fragrance and coloring agents may also be included. The CTFA CosmeticIngredient Handbook, Seventh Edition, 1997 and the Eighth Edition, 2000,which are incorporated by reference herein in their entirety, describesa wide variety of ingredients commonly used in skin care compositions,which are suitable for use in the compositions of the present invention.Other topically-applied compounds are listed in Remington'sPharmaceutical Sciences, 20th Ed., Lippincott Williams & Witkins,Baltimore, Md. (2000) (hereinafter Remington's), U.S. Pharmacopeia andNational Formulary, The United States Pharmacopeial Convention, Inc.,Rockville, Md. and Physician's Desk Reference, Medical Economics Co.,Inc., Oradell, N.J. incorporated herein by reference. The concentrationof the other active ingredient in formulations provided by the inventionis that which provides an effective amount of the other activeingredient; these concentrations are well-known in the art. See, e.g.,the above references, as well as Textbook of Dermatology, Champion,Burton, Burns, and Bretnach, eds., Blackwell Publishing, 1998. Furtherexamples of cosmetic and/or pharmaceutical ingredients which aresuitable for use in compositions of the present invention are disclosedin U.S. Patent Publication Nos. 2004/0180020, 2005/0142095 and U.S. Pat.No. 6,277,892.

III. Methods of Administration

Compositions according to the present invention may be applied to theskin in any number of forms or vehicles known to those of skill in theart including: (i) aqueous, aqueous-alcoholic or oily solutions,optionally gelled; (ii) emulsions obtained by dispersing an aqueousphase in an oil or silicone phase, or vice versa (i.e., water-in-oil,oil-in-water, water-in-silicone, silicone-in-water); (iii) tripleemulsions (i.e., water-in-oil-in-water or oil-in-water-in-oil); or (iv)vesicular dispersions. The viscosity of the final formulation may bemodulated by methods known in the art to form a cream, lotion, gel,serum or spray. Any form of applicator known in the art is also includedin the methods of administering the compositions of the invention.

IV. Methods of Use

One aspect of the present invention is directed to a method for reducingthe appearance of biological and/or environmentally-caused aging bytopically-applying to the skin of a human, a dermatological or cosmeticcomposition comprising: (a) telomerase; (a) a telomerase; (b) one ormore growth factors; (c) at least two acylated peptides; and (d)optionally, at least one skin benefit agent selected from the groupconsisting of antioxidants, humectants and moisturizing agents. In otherembodiments of the methods of use, the composition contains an EpidermalGrowth Factor, at least one Keratinocyte Growth Factor, TransformingGrowth Factor-β1, and a telomerase, which provides surprisinglyefficacious use in topical treatment of skin. In yet other embodimentsthe methods of use, the composition contains an Epidermal Growth Factor,at least one Keratinocyte Growth Factor, Transforming Growth Factor-β1,and an antibody to telomerase, which provides surprisingly efficacioususe in topical treatment of skin.

In some embodiments of the invention, the compositions described hereinare applied topically to the skin of a human to reduce inflammation fromeither intrinsic or extrinsic sources. In other embodiments of theinvention, the compositions described herein are applied topically tothe skin of a human to reduce oxidative stress from either extrinsic orintrinsic sources. In other embodiments of the invention, thecompositions described herein are applied topically to the skin of ahuman to produce a skin brightening effect. In other embodiments of theinvention, the compositions described herein are applied topically tothe skin of a human to reduce fine lines and wrinkles in skin. In someother embodiments of the invention, the compositions described hereinare applied topically to the skin of a human to enhance elasticity ofskin. In other embodiments of the invention, the compositions describedherein are applied topically to the skin of a human to reduce theappearance of scarring and lesions of the skin due to extrinsic andintrinsic factors

As used in the present invention, by the phrase “signs of biological orenvironmentally-caused aging biological or environmentally-caused aging”is meant fine lines, wrinkles, furrows, age spots and/or reduced skinelasticity. Reduction in the appearance of fine lines and wrinkles canbe measured by a number of techniques known to those of skill in the artand including clinical assessment by a trained observer (e.g., doctor,nurse, technician) or instrumentally (e.g., by use of Silflo replicamasks or an imaging system such as VISTA from Canfield Scientific.)

Topical application may be more than about once, twice, three times,four times, five times, or six times per week, or more than once, twice,three times, four times, five times, or six times per day. Frequency ofapplication may be less than about twice, three times, four times, fivetimes, or six times per week, or less than about once, twice, threetimes, four times, five times, or six times per day. Some embodiments ofthe invention provide a method for cosmetic treatment of the skin of anindividual by topical administration of an effective amount of thecomposition of the invention. In some embodiments, the composition isadministered an average of about once per day; in some embodiments, thecomposition is administered an average of about once or twice per day;in some embodiments, the composition is administered an average of aboutonce to three times per day; in some embodiments, the composition isadministered an average of more than about three times per day. In oneembodiment, the composition is administered an average of about twiceper day, typically in the morning upon rising and in the evening beforeretiring.

V. Kits

In still another aspect, the present invention provides kits for thecosmetic treatment of skin or to produce a desired cosmetic result.These kits comprise the compositions described herein, in a container orcontainers which are held in suitable packaging. In some embodiments thekits further contain instructions teaching the use of the kit accordingto the various methods and approaches described herein. Such kits mayalso include information, such as scientific literature references,package insert materials, cosmetic trial results, and/or summaries ofthese and the like, which indicate or establish the activities and/oradvantages of the composition. Such information may be based on theresults of various studies, for example, studies using experimentalanimals involving in vivo models and studies based on human cosmetic orclinical trials. Kits described herein can be provided, marketed and/orpromoted to health care providers (e.g., dermatologists and otherphysicians), skin care appearance care providers, includingcosmetologists, hair stylists, and the like. Kits for cosmetic use mayalso be provided, marketed and/or promoted directly to consumers. Kitsmay be marketed in spas and retail outlets.

VI. Examples

The components and specific ingredients are exemplary only, and do notlimit the modifications which can be made within the scope of theinvention.

Example 1 Skin Care Composition I

TABLE I INGREDIENT w/w % D.I. WATER Q.S. to 100% ALLANTOIN 0.10PANTHENOL 1.00 BUTYLENE GLYCOL 2.00 MAGNESIUM ALUMINUM SILICATE 0.30XANTHAN GUM 0.30 GLYCERIN 3.00 CETEARYL ALCOHOL 2.50 CETEARETH 20GLYCERYL STEARATE 1.00 SUNFLOWER OIL 3.50 + 0.50 MEADOWFOAM SEED OIL1.00 SHEA BUTTER 1.00 MANGO BUTTER 0.50 AVOCADO BUTTER 0.50 DIMETHICONE2.00 LINOLEIC ACID, 0.25 LINOLENIC ACID, TOCOPHEROL DL-ALPHA TOCOPHERYLACETATE 0.001 PHENOXYETHANOL 1.00 METHYLPARABEN BUTYLPARABENPROPYLPARABEN ETHYLPARABEN SODIUM HYALURONATE 1.00 JAPANESE GREEN TEAEXTRACT 0.50 METHYLSILANOL MANNURONATE 1.00 CYCLOPENTASILOXANE 0.50DIMETHICONE/VINYL DIMETHICONE CROSSPOLYMER UBIQUINONE 0.30 CERAMIDES3.00 PEG-40 HYDROGENATED CASTOR OIL PALMITOYL PENTAPEPTIDE-4 3.00MYRISTOYL PENTAPEPTIDE -8 0.50 MYRISTOYL PENTAPEPTIDE -11 0.50 HUMANTELOMERASE REVERSE 0.0006 TRANSCRIPTASE KGF-1 0.00006 EGF 0.00015 TGF-β1 0.00002

Example 2 Skin Care Composition II

TABLE II INGREDIENT w/w % D.I. WATER Q.S. to 100% ALLANTOIN 0.10PANTHENOL 1.00 BUTYLENE GLYCOL 2.00 MAGNESIUM ALUMINUM SILICATE 0.30XANTHAN GUM 0.30 GLYCERIN 3.00 CETEARYL ALCOHOL 2.50 CETEARETH 20GLYCERYL STEARATE 1.00 SUNFLOWER OIL 3.50 + 0.50 MEADOWFOAM SEED OIL1.00 SHEA BUTTER 1.00 MANGO BUTTER 0.50 AVOCADO BUTTER 0.50 DIMETHICONE2.00 LINOLEIC ACID, 0.25 LINOLENIC ACID, TOCOPHEROL DL-ALPHA TOCOPHERYLACETATE 0.001 PHENOXYETHANOL 1.00 METHYLPARABEN BUTYLPARABENPROPYLPARABEN ETHYLPARABEN SODIUM HYALURONATE 1.00 JAPANESE GREEN TEAEXTRACT 0.50 METHYLSILANOL MANNURONATE 1.00 CYCLOPENTASILOXANE 0.50DIMETHICONE/VINYL DIMETHICONE CROSSPOLYMER UBIQUINONE 0.30 CERAMIDES3.00 PEG-40 HYDROGENATED CASTOR OIL PALMITOYL PENTAPEPTIDE-4 3.00MYRISTOYL PENTAPEPTIDE -8 0.50 MYRISTOYL PENTAPEPTIDE -11 0.50 ANTIBODYTO HUMAN TELOMERASE 0.0006 REVERSE TRANSCRIPTASE KGF-1 0.00006 EGF0.00015 TGF- β1 0.00002

Example 3 Skin Care Composition III

TABLE III INGREDIENT w/w % D.I. WATER Q.S. to 100% ALLANTOIN 0.10PANTHENOL 1.00 BUTYLENE GLYCOL 2.00 MAGNESIUM ALUMINUM SILICATE 0.30XANTHAN GUM 0.30 GLYCERIN 3.00 CETEARYL ALCOHOL 2.50 CETEARETH 20GLYCERYL STEARATE 1.00 SUNFLOWER OIL 3.50 + 0.50 MEADOWFOAM SEED OIL1.00 SHEA BUTTER 1.00 MANGO BUTTER 0.50 AVOCADO BUTTER 0.50 DIMETHICONE2.00 LINOLEIC ACID, 0.25 LINOLENIC ACID, TOCOPHEROL DL-ALPHA TOCOPHERYLACETATE 0.001 PHENOXYETHANOL 1.00 METHYLPARABEN BUTYLPARABENPROPYLPARABEN ETHYLPARABEN SODIUM HYALURONATE 1.00 JAPANESE GREEN TEAEXTRACT 0.50 METHYLSILANOL MANNURONATE 1.00 CYCLOPENTASILOXANE 0.50DIMETHICONE/VINYL DIMETHICONE CROSSPOLYMER UBIQUINONE 0.30 CERAMIDES3.00 PEG-40 HYDROGENATED CASTOR OIL PALMITOYL PENTAPEPTIDE-4 3.00MYRISTOYL PENTAPEPTIDE -8 0.50 MYRISTOYL PENTAPEPTIDE -11 0.50 HUMANTELOMERASE REVERSE 0.0006 TRANSCRIPTASE and HUMAN TELOMERASE RNA KGF-10.00006 EGF 0.00015 TGF- β1 0.00002

Example 4 Skin Care Composition IV

TABLE IV INGREDIENT w/w % D.I. WATER Q.S. to 100% ALLANTOIN 0.10PANTHENOL 1.00 BUTYLENE GLYCOL 2.00 MAGNESIUM ALUMINUM SILICATE 0.30XANTHAN GUM 0.30 GLYCERIN 3.00 CETEARYL ALCOHOL 2.50 CETEARETH 20GLYCERYL STEARATE 1.00 SUNFLOWER OIL 3.50 + 0.50 MEADOWFOAM SEED OIL1.00 SHEA BUTTER 1.00 MANGO BUTTER 0.50 AVOCADO BUTTER 0.50 DIMETHICONE2.00 LINOLEIC ACID, 0.25 LINOLENIC ACID, TOCOPHEROL DL-ALPHA TOCOPHERYLACETATE 0.001 PHENOXYETHANOL 1.00 METHYLPARABEN BUTYLPARABENPROPYLPARABEN ETHYLPARABEN SODIUM HYALURONATE 1.00 JAPANESE GREEN TEAEXTRACT 0.50 METHYLSILANOL MANNURONATE 1.00 CYCLOPENTASILOXANE 0.50DIMETHICONE/VINYL DIMETHICONE CROSSPOLYMER UBIQUINONE 0.30 CERAMIDES3.00 PEG-40 HYDROGENATED CASTOR OIL PALMITOYL PENTAPEPTIDE-4 3.00MYRISTOYL PENTAPEPTIDE -8 0.50 MYRISTOYL PENTAPEPTIDE -11 0.50 HUMANTELOMERASE REVERSE 0.0006 TRANSCRIPTASE and HUMAN TELOMERASE RNA KGF-10.00006 VEGF 0.00015 TGF- β1 0.00002

Example 5 Skin Care Composition V

TABLE V INGREDIENT w/w % D.I. WATER Q.S. to 100% ALLANTOIN 0.10PANTHENOL 1.00 BUTYLENE GLYCOL 2.00 MAGNESIUM ALUMINUM SILICATE 0.30XANTHAN GUM 0.30 GLYCERIN 3.00 CETEARYL ALCOHOL 2.50 CETEARETH 20GLYCERYL STEARATE 1.00 SUNFLOWER OIL 3.50 + 0.50 MEADOWFOAM SEED OIL1.00 SHEA BUTTER 1.00 MANGO BUTTER 0.50 AVOCADO BUTTER 0.50 DIMETHICONE2.00 LINOLEIC ACID, 0.25 LINOLENIC ACID, TOCOPHEROL DL-ALPHA TOCOPHERYLACETATE 0.001 PHENOXYETHANOL, 1.00 METHYLPARABEN BUTYLPARABENPROPYLPARABEN ETHYLPARABEN SODIUM HYALURONATE 1.00 JAPANESE GREEN TEAEXTRACT 0.50 METHYLSILANOL MANNURONATE 1.00 CYCLOPENTASILOXANE 0.50DIMETHICONE/VINYL DIMETHICONE CROSSPOLYMER UBIQUINONE 0.30 CERAMIDES3.00 PEG-40 HYDROGENATED CASTOR OIL PALMITOYL PENTAPEPTIDE-4 3.00MYRISTOYL PENTAPEPTIDE -8 0.50 MYRISTOYL PENTAPEPTIDE -11 0.50 ANTIBODYTO HUMAN TELOMERASE 0.0006 REVERSE TRANSCRIPTASE KGF-1 0.00006 VEGF0.00015 TGF- β1 0.00002

Example 6 Skin Care Composition VI

TABLE VI INGREDIENT w/w % D.I. WATER Q.S. to 100% ALLANTOIN 0.10PANTHENOL 1.00 BUTYLENE GLYCOL 2.00 MAGNESIUM ALUMINUM SILICATE 0.30XANTHAN GUM 0.30 GLYCERIN 3.00 CETEARYL ALCOHOL 2.50 CETEARETH 20GLYCERYL STEARATE 1.00 SUNFLOWER OIL 3.50 + 0.50 MEADOWFOAM SEED OIL1.00 SHEA BUTTER 1.00 MANGO BUTTER 0.50 AVOCADO BUTTER 0.50 DIMETHICONE2.00 LINOLEIC ACID, 0.25 LINOLENIC ACID, TOCOPHEROL DL-ALPHA TOCOPHERYLACETATE 0.001 PHENOXYETHANOL, 1.00 METHYLPARABEN BUTYLPARABENPROPYLPARABEN ETHYLPARABEN SODIUM HYALURONATE 1.00 JAPANESE GREEN TEAEXTRACT 0.50 METHYLSILANOL MANNURONATE 1.00 CYCLOPENTASILOXANE 0.50DIMETHICONE/VINYL DIMETHICONE CROSSPOLYMER UBIQUINONE 0.30 CERAMIDES3.00 PEG-40 HYDROGENATED CASTOR OIL PALMITOYL PENTAPEPTIDE-4 3.00MYRISTOYL PENTAPEPTIDE -8 0.50 MYRISTOYL PENTAPEPTIDE -11 0.50 HUMANTELOMERASE REVERSE 0.0006 TRANSCRIPTASE KGF-1 0.00006 VEGF 0.00015 TGF-β1 0.00002

Example 7 Method of Preparing the Composition of Example 1

The composition of Example 1 is prepared by combining the components ofdeionized water, allantoin, pathenol, buylene glycol, magnesium aluminumsilicate, xanthan gum, and glycerin in the proportions given in Table 1,in a first mixing kettle forming Mixture 1. Mixture 1 is heated to about70° C. to about 75° C., and mixed until uniform and smooth. In a secondmixing kettle, cetearyl alcohol, ceteareth 20, glyceryl stearate,sunflower oil, meadowfoam seed oil, shea butter, mango butter, avocadobutter, dimethicone, linoleic acid, linolenic acid, and tocopherol arecombined in the proportions given in Table 1, forming Mixture 2. Mixture2 is heated to about 70° C. to about 75° C. until the mixture is meltedcompletely, and no visible solids remained. After the melting step forMixture 2 is completed, and both Mixture 1 and Mixture 2 are both atabout 70° C. to about 75° C., Mixture 2 is added to Mixture 1 withmixing until the combined Mixture 1 in the first mixing kettle is smoothand uniform. The combined Mixture 1 in the first mixing kettle is thencooled to about 40° C.

Mixture 3, which is made from combining DL-tocopherol acetate,phenoxyethanol, methylparaben, butylparaben, propylparaben,ethylparaben, sodium hyaluronate, Japanese green tea extract,methylsilanol mannuronate, cyclopentasiloxane, and dimethicone/vinyldiemethicone crosspolymer in the proportions given in Table 1, is addedto the combined Mixture 1 in the first mixing kettle after combinedMixture 1 is cooled to 40° C. Mixing is continued in the first mixingkettle, until Mixture 1 is uniform and smooth. A group of componentsincluding ubiquinone, sunflower oil, ceramides, PEG-40 hydrogenatedcastor oil, palmitoyl pentapeptide-4, myristoyl pentapeptide-8, andmyristoyl pentapeptide-11 are added to Mixture 1 in the first mixingkettle in the proportions given in Table 1, with continued mixing untilthe augmented Mixture 1 is smooth and uniform. The last addition ofcomponents includes human Telomerase RT, KGF-1, EGF, and TGF-β1 in theproportions given in Table 1, which is made to Mixture 1 in the firstmixing kettle. Stirring is continued until the composition is smooth anduniform.

Example 8 Method of Preparing the Composition of Example 5

The composition of Example 5 is prepared by combining the components ofdeionized water, allantoin, pathenol, buylene glycol, magnesium aluminumsilicate, xanthan gum, and glycerin in the proportions given in Table 5,in a first mixing kettle forming Mixture 1. Mixture 1 is heated to about70° C. to about 75° C., and mixed until uniform and smooth. In a secondmixing kettle, cetearyl alcohol, ceteareth 20, glyceryl stearate,sunflower oil, meadowfoam seed oil, shea butter, mango butter, avocadobutter, dimethicone, linoleic acid, linolenic acid, and tocopherol arecombined in the proportions given in Table 5, forming Mixture 2. Mixture2 is heated to about 70° C. to about 75° C. until the mixture is meltedcompletely, and no visible solids remained. After the melting step forMixture 2 is completed, and both Mixture 1 and Mixture 2 are both atabout 70° C. to about 75° C., Mixture 2 is added to Mixture 1 withmixing until the combined Mixture 1 in the first mixing kettle is smoothand uniform. The combined Mixture 1 in the first mixing kettle is thencooled to about 40° C.

Mixture 3, which is made from combining DL-tocopherol acetate,phenoxyethanol, methylparaben, butylparaben, propylparaben,ethylparaben, sodium hyaluronate, Japanese green tea extract,methylsilanol mannuronate, cyclopentasiloxane, and dimethicone/vinyldiemethicone crosspolymer in the proportions given in Table 5, is addedto the combined Mixture 1 in the first mixing kettle after combinedMixture 1 is cooled to 40° C. Mixing is continued in the first mixingkettle, until Mixture 1 is uniform and smooth. A group of componentsincluding ubiquinone, sunflower oil, ceramides, PEG-40 hydrogenatedcastor oil, palmitoyl pentapeptide-4, myristoyl pentapeptide-8, andmyristoyl pentapeptide-11 are added to Mixture 1 in the first mixingkettle in the proportions given in Table 5, with continued mixing untilthe augmented Mixture 1 is smooth and uniform. The last addition ofcomponents includes antibody to human Telomerase RT, KGF-1, VEGF, andTGF-β1 in the proportions given in Table 5, which is made to Mixture 1in the first mixing kettle. Stirring is continued until the compositionis smooth and uniform.

While preferred embodiments of the present invention have been shown anddescribed herein, it will be obvious to those skilled in the art thatsuch embodiments are provided by way of example only. Numerousvariations, changes, and substitutions will now occur to those skilledin the art without departing from the invention. It should be understoodthat various alternatives to the embodiments of the invention describedherein may be employed in practicing the invention. It is intended thatthe following claims define the scope of the invention and that methodsand structures within the scope of these claims and their equivalents becovered thereby.

What is claimed is:
 1. A method for improving the appearance of skin ina human subject, comprising topically applying to the skin of the humansubject a composition comprising: an Epidermal Growth Factor; aKeratinocyte Growth Factor; a Transforming Growth factor-beta 1; anacylated peptide; a coenzyme Q; and a cosmetically suitable vehicle;wherein applying said composition to the skin of the human subjectresults in an improvement in the appearance of the skin which isselected from the group consisting of: reduced inflammation of the skin,reduced oxidative stress of the skin, skin brightening, reduced finelines of the skin, reduced wrinkles of the skin, enhanced elasticity ofthe skin, and reduced appearance of scarring and lesions.
 2. The methodof claim 1, wherein the acylated peptide is a palmitoylated peptide. 3.The method of claim 1, wherein the acylated peptide is a myristoylatedpeptide.
 4. The method of claim 1, further comprising a fatty acid. 5.The method of claim 1, further comprising alpha hydroxy acids (AHAs). 6.The method of claim 1, further comprising at least one skin benefitagent selected from the group consisting of at least one humectants,moisturizing agents, and anti-inflammatory agents.
 7. The method ofclaim 1, further comprising an agent which promotes growth of telomeresof cells in the skin.
 8. The method of claim 7, wherein the improvementin the appearance of the skin involves prolonging viability of the cellsin the skin.
 9. The method of claim 1, wherein the composition isapplied topically for more than once a day.
 10. The method of claim 1,wherein the composition is applied topically for less than six times aweek.